canagliflozin profile

canagliflozin hydrate : A hydrate that is the hemihydrate form of canagliflozin. Used for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	24812758
CHEMBL ID	2048484
CHEBI ID	73274
SCHEMBL ID	157162
MeSH ID	M0550188

Synonym
HY-10451
842133-18-0
(2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
CANAGLIFLOZIN ,
jnj-28431754
ta-7284
ta 7284
invokana
jnj 28431754
BCP9000477
bdbm50386885
canagliflozin hydrate
6s49dgr869 ,
jnj 24831754
hsdb 8284
canagliflozin [inn]
jnj 24831754zae
(1s)-1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-d-glucitol
canagliflozin anhydrous
unii-6s49dgr869
(1s)-1,5-anhydro-1-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-d-glucitol
jnj 24831754aaa
1-(glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene
d-glucitol, 1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1s)-
d-glucitol, 1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1s)-
chebi:73274 ,
CHEMBL2048484
(1s)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-d-glucitol
BCPP000303
canagliflozin [mi]
canagliflozin [who-dd]
d-glucitol, 1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-
(1s)-1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-d- glucitol
CS-0522
S2760
(1s)-1,5-anhydro-1-c-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol
(1s)-1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-d-glucitol
(2s,3r,4r,5s,6r)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
gtpl4582
DB08907
smr004702906
MLS006011126
SCHEMBL157162
J-500391
(1s)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methyl-phenyl)-d-glucitol
XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
AC-26303
AKOS025401827
(2s,3r,4r,5s,6r)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
CCG-229581
jnj 28431754aaa
KS-1443
mfcd18251436
SW219119-1
Q5030940
AMY3291
NCGC00346691-02
d-glucitol,1,5-anhydro-1-c-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1s)-
jnj24831754zae; ta 7284;(2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2h-pyran-3,4,5-triol
A25050
DTXSID601004469
EN300-6733492
Z2235801995

Excerpt	Reference	Relevance
"Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM)."	( Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. Arakawa, K; Conway, B; Conway, J; Demarest, K; Du, F; Kuriyama, C; Liang, Y; Liu, Y; Martin, T; Matsushita, Y; Polidori, D; Ueta, K; Ways, K; Xu, J, 2012)	2.22
"Canagliflozin (CANA) is a sodium-glucose cotransporter 2 inhibitor that was recently approved for treating diabetes. "	( Canagliflozin Improves Liver Function in Rats by Upregulating Asparagine Synthetase. Ding, Y; Dong, R; Meng, S; Wang, H; Wang, S; Yin, L, 2021)	3.51
"Canagliflozin is a sodium–glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose levels by increasing urinary glucose excretion. "	( Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance. Hamada, K; Inagaki, N; Iwasaki, T; Mori-Anai, K; Nangaku, M; Sakata, Y; Sasaki, K, 2022)	2.43
"Canagliflozin is an antidiabetic medicine that inhibits sodium-glucose cotransporter 2 (SGLT2) in proximal tubules. "	( Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice. Chen, WA; Chen, X; Cong, XX; Li, ZZ; Lin, YN; Lu, XM; Lv, XH; Nan, JL; Shen, J; Su, L; Wang, BB; Wang, ZT; Zhou, RY; Zhu, QL, 2022)	2.49
"Canagliflozin is a sodium glucose-cotransporter-2 receptor inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). "	( Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis. Geng, Q; Hou, F; Wang, Z; Zhang, Y; Zhao, M, 2022)	2.45
"Canagliflozin is an oral hypoglycemic drug recently formulated in combination with a biguanide, metformin hydrochloride, for improving its hypoglycemic action. "	( Ecofriendly appraisal of stability-indicating high-performance chromatographic assay of canagliflozin and metformin with their toxic impurities; in silico toxicity prediction. Emam, AA; Emam, RA, 2023)	2.58
"Canagliflozin (CANA) is an SGLT2i, which is widely prescribed, to reduce cardiovascular complications, and as a second-line therapy after metformin in the treatment of type 2 diabetes mellitus."	( Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice. Bergamo, ETP; Bromage, TG; Chlebek, C; Dixit, M; Harrison, DE; Hu, B; Ladiges, W; Mijares, DQ; Miller, RA; Poudel, SB; Rosen, CJ; Ruff, RR; Strong, R; Witek, L; Yakar, S; Yildirim, G, 2023)	1.95
"Canagliflozin (CFZ) is a sodium-glucose cotransporter-2 inhibitor (SGLT2) that lowers albuminuria in type-2 diabetic patients, cardiovascular, kidney, and liver disease. "	( Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, Abdelaal, N; Alshawwa, SZ; El-Nabarawi, MA; Elfar, N; Elnawawy, T; Elrefai, MFM; Elzohairy, NA; Fathy Elhabal, S; Gad, RA; Ghaffar, SA; Hamdan, AME; Khalifa, MM; Khasawneh, MA; Mohammed, H; Mohie, PM; Saied, EM; Waggas, DS, 2023)	2.71
"Canagliflozin is a promising drug for treatment of ID horses that requires future studies."	( Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: A randomized, placebo-controlled, double-blind, study. Bergsten, P; Bröjer, J; Forslund, A; Lindåse, S; Nostell, K, )	1.89
"Canagliflozin is a widely used antihyperglycemic agent, a sodium-glucose cotransporter-2 (SGLT2) inhibitor that enhances urinary glucose excretion."	( Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF-κB and Nrf2/PPAR-γ/SIRT1 signaling pathways. Ali, FEM; Althagafy, HS; Atwa, AM; Hassanein, EHM; Kotb El-Sayed, MI; Mohammedsaleh, ZM; Sayed, AM; Soubh, AA, 2023)	3.07
"Canagliflozin (CANA) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with blood glucose lowering effects. "	( Sex-dependent effects of Canagliflozin on kidney protection in mice with combined hypertension-type 1 diabetes. Cheff, V; Gutsol, A; Hébert, RL; Trentin-Sonoda, M, 2023)	2.66
"Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor which received U.S. "	( Canagliflozin-induced Fanconi syndrome in a patient with previously unrecognized type 1 diabetes. Broussard, J; Dziuba, M; Khan, N; Tso, K, 2019)	3.4
"Canagliflozin is a US FDA-approved SGLT2 inhibitor that has demonstrated CV and renal outcome benefits in large scale placebo-controlled randomized trials of patients with Type 2 diabetes mellitus and elevated CV risk."	( Canagliflozin and cardiovascular outcomes in Type 2 diabetes. Mahaffey, KW; Rodriguez, F; Sarraju, A; Spencer-Bonilla, G, 2021)	2.79
"Canagliflozin (CANA) is a sodium‑glucose co‑transporter 2 inhibitor used for the clinical treatment of diabetes."	( Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A. Ding, J; He, L; Pang, S; Shen, B; Xie, X; Xu, D; Zhou, C; Zhou, Y, 2020)	1.59
"Canagliflozin (Cana) is an FDA-approved diabetes drug that protects against cardiovascular and kidney diseases. "	( Canagliflozin extends life span in genetically heterogeneous male but not female mice. Allison, DB; Bogue, M; Debarba, L; Diaz, V; Fernandez, E; Galecki, A; Garvey, WT; Harrison, DE; Javors, MA; Jayarathne, H; Kumar, N; Ladiges, WC; Lombard, DB; Macchiarini, F; Miller, RA; Nelson, J; Reifsnyder, P; Rosenthal, NA; Sadagurski, M; Salmon, AB; Smith, DL; Snyder, JM; Strong, R, 2020)	3.44
"Canagliflozin is an SGLT2 inhibitor that provides sustained reductions in HbA1c, blood pressure and weight."	( Canagliflozin: metabolic, cardiovascular and renal protection. Barrios, V; Escobar, C, 2021)	2.79
"Canagliflozin is an antidiabetic agent which lowers blood glucose levels by inhibiting the glucose reabsorption machinery in the proximal tubules. "	( Canagliflozin ameliorates aortic and hepatic dysfunction in dietary-induced hypercholesterolemia in the rabbit. Abdelaziz, RR; Ashry, NA; Saleh, MA; Suddek, GM, 2021)	3.51
"Canagliflozin (CAN) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes mellitus. "	( Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action. Ali, EHA; Arafa, NMS; Hassan, MK, 2017)	3.34
"Canagliflozin is a newly approved drug for type II diabetes mellitus. "	( Canagliflozin stability study and ecofriendly chromatographic determination of its degradation product: A comparative study. Emam, AA, 2018)	3.37
"Canagliflozin is a sodium-glucose cotransporter (SGLT) 2 inhibitor, and it also exerts a modest inhibitory effect on SGLT1."	( Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model. Abe, T; Asaji, K; Fukuda, NN; Fukuda, S; Ho, HJ; Ito, S; Kanemitsu, Y; Kikuchi, K; Matsumoto, Y; Mishima, E; Mukawa, C; Nanto, F; Saigusa, D; Soga, T; Suzuki, C; Suzuki, T; Tachikawa, T; Tomioka, Y; Tsukamoto, H; Tsukimi, T, 2018)	2.64
"Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. "	( Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Barrett, TD; de Zeeuw, D; Desai, M; Figtree, G; Fulcher, G; Mahaffey, KW; Matthews, DR; Neal, B; Perkovic, V; Rådholm, K; Shaw, W; Solomon, SD, 2018)	3.37
"Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that is currently available for the management of type 2 diabetes mellitus. "	( Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice. Abdelrahman, AM; Al Suleimani, Y; Ali, BH; Ashique, M; Manoj, P; Nemmar, A; Shalaby, A, 2019)	2.36
"Canagliflozin is a novel drug for diabetes mellitus with the mechanisms of inducing glucosuria through inhibition of the sodium-glucose cotransporter 2 in the kidney independent of insulin activity. "	( Metabolic Acidosis in Postsurgical Patient on Canagliflozin and Metformin: A Case Report. Darwish, AM, 2019)	2.21
"Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose, as well as blood pressure, body weight, and albuminuria in patients with type 2 diabetes mellitus (T2DM). "	( The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Carbone, S; Dixon, DL, 2019)	2.23
"Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). "	( Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Meininger, G; Usiskin, K; Wajs, E; Xi, L; Yale, JF; Yue, D, 2013)	2.14
"Canagliflozin is an orally administered sodium glucose cotransporter 2 inhibitor proposed for the treatment of type 2 diabetes. "	( Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Davis, SN; Lamos, EM; Younk, LM, 2013)	3.28
"Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). "	( Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Bode, B; Fung, A; Stenlöf, K; Sullivan, D; Usiskin, K, 2013)	2.14
"Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for treatment of type 2 diabetes mellitus (T2DM). "	( Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C, 2014)	2.13
"Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). "	( Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP, 2013)	2.14
"Canagliflozin is a newly approved drug for the treatment of type 2 diabetes. "	( Safety of canagliflozin in patients with type 2 diabetes. Mikhail, N, 2014)	2.25
"Canagliflozin is an oral antihyperglycemic agent used for the treatment of type 2 diabetes mellitus. "	( Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Chen, J; Cuyckens, F; Devineni, D; Evans, DC; Johnson, MD; Kalamaridis, D; Kelley, MF; Lim, HK; Lin, R; Mamidi, RN; Scheers, E; Sha, S; Silva, J, 2014)	2.14
"Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). "	( Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Bode, B; Desai, M; Fung, A; Harris, S; Mayer, C; Meininger, G; Shaw, W; Sinclair, A; Usiskin, K; Vijapurkar, U, 2014)	2.16
"Canagliflozin (Invokana™) is an orally administered sodium-glucose co-transporter-2 (SGLT2) inhibitor used in the treatment of patients with type 2 diabetes. "	( Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Plosker, GL, 2014)	3.29
"Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed for treating type 2 diabetes mellitus (T2DM)."	( Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Fung, A; Kline, I; Mayer, C; Meininger, G; Usiskin, K, 2014)	2.14
"Canagliflozin is a sodium glucose co-transporter 2 inhibitor approved for treating patients with type 2 diabetes. "	( Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Artis, E; Berg, JK; Devineni, D; Morrow, L; Polidori, D; Rusch, S; Stein, P; Vaccaro, N, 2014)	3.29
"Canagliflozin is an SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus. "	( Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin. Bryant, S; De Jonghe, S; Feyen, B; Johnson, MD; Kelley, MF; Lammens, G; Louden, C; Ma, JY; Mamidi, RN; Moesen, E; Proctor, J; Snook, S; Vinken, P; Ways, K, 2014)	2.06
"Canagliflozin is a sodium glucose cotransporter 2 inhibitor for patients with type 2 diabetes and can be given as monotherapy or in combination with other agents, including insulin. "	( Canagliflozin: a new option for managing diabetes. Clements, JN; Livingston, M, 2014)	3.29
"Canagliflozin is a new drug in class of sodium-glucose cotransporter 2 inhibitors used for treatment of type 2 diabetes mellitus. "	( Canagliflozin-Associated Acute Pancreatitis. Verma, R, )	3.02
"Canagliflozin is a sodium glucose co-transporter 2 inhibitor that has been shown to improve glycemic control in type 2 diabetes mellitus (T2DM). "	( Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Buysman, EK; Chow, W; Henk, HJ; Rupnow, MF, 2015)	2.08
"Canagliflozin is a sodium-glucose cotransporter 2 inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM). "	( Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curtin, CR; Devineni, D; Marbury, TC; Rusch, S; Smith, W; Stieltjes, H; Vaccaro, N; Vandebosch, A; Wajs, E; Wexler, D, 2015)	2.1
"Canagliflozin is an inhibitor of sodium-glucose cotransporters type 2 (SGLT2) that are present in renal tubules. "	( [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes]. Scheen, AJ, 2014)	2.76
"Canagliflozin is an orally active, reversible, selective SGLT2 inhibitor."	( Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Devineni, D; Polidori, D, 2015)	1.37
"Canagliflozin is a competitive, reversible, highly selective SGLT2 inhibitor and available in 100mg and 300mg as oral tablet form. "	( A Systematic Review on Effect of Canagliflozin in Special Population. Gohel, K; Patel, BG; Patel, S, 2016)	2.16
"Canagliflozin is a sodium glucose co-transporter 2 inhibitor approved worldwide for the treatment of patients with type 2 diabetes mellitus (T2DM). "	( Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Iijima, H; Inagaki, N; Kifuji, T; Maruyama, N, 2015)	2.11
"Canagliflozin is a potential option as an add-on to metformin based on its improvement in HbA1c, FPG, body weight, and β cell function, but further studies are demanded to strengthen this evidence. "	( Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis. Cui, Y; Lu, M; Ma, L; Yang, T; Zhou, Y, 2015)	2.15
"Canagliflozin is an orally active, reversible, selective sodium-glucose co-transporter-2 inhibitor. "	( Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. De Winter, W; Devineni, D; Dunne, A; Hoeben, E; Neyens, M; Vermeulen, A, 2016)	2.15
"Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM)."	( Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. Bilezikian, JP; Fung, A; Polidori, D; Rosenthal, N; Sullivan, D; Usiskin, K; Watts, NB, 2016)	2.09
"Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM)."	( Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. Bilezikian, JP; Desai, M; Edwards, R; Law, G; Meininger, G; Usiskin, K; Watts, NB, 2016)	2.27
"Canagliflozin is a novel, orally selective inhibitor of sodium-dependent glucose co-transporter-2 (SGLT2) for the treatment of patients with type 2 diabetes mellitus. "	( A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. Ito, Y; Kobuchi, S; Sakaeda, T; Yano, K, 2016)	2.13
"Canagliflozin is a recently developed sodium-glucose cotransporter (SGLT) 2 inhibitor that promotes renal glucose excretion and is considered to inhibit renal SGLT2 from the luminal side of proximal tubules. "	( Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. Mori, K; Nakamaru, Y; Saito, R; Shimizu, M; Yamazaki, H, 2016)	2.08
"Canagliflozin is a recently approved drug for use in the treatment of type 2 diabetes. "	( In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Cuyckens, F; Dallas, S; Evans, DC; Johnson, MD; Kelley, MF; Leclercq, L; Lim, HK; Mamidi, RNVS; Scheers, E; Sensenhauser, C; Snoeys, J; Verboven, P, 2017)	2.11
"Canagliflozin is a new SGLT2 inhibitor which has been approved as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D) mellitus in more than 30 countries. "	( Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Chang, F; Xiao, MY; Xiong, W; Zhang, M, 2016)	2.19
"Canagliflozin is an SGLT2 inhibitor approved for the treatment of type-2 diabetes. "	( Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin. de Trixhe, XW; de Winter, W; Devineni, D; Dunne, A; Hsu, CH; Pinheiro, J; Polidori, D, 2017)	2.09
"Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that is being investigated for the treatment of type 2 diabetes mellitus (T2DM)."	( Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Devineni, D; Hompesch, M; Morrow, L; Murphy, J; Schwartz, S; Skee, D; Vandebosch, A; Ways, K, 2012)	3.26
"Canagliflozin is a sodium glucose co-transporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). "	( Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Alba, M; Canovatchel, W; Cefalu, WT; Kim, KA; Meininger, G; Stenlöf, K; Tong, C; Usiskin, K, 2013)	2.14

Excerpt	Reference	Relevance
"Canagliflozin has a robust inhibitory effect on sodium glucose transporter (SGLT)-2 and a mild inhibitory effect on SGLT1. "	( Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial. Hara, K; Inukai, T; Naruse, R; Suetsugu, M; Takebayashi, K; Terasawa, T; Tsuchiya, T, 2017)	2.3
"Canagliflozin has a low risk of hypoglycaemia and was generally well tolerated in clinical trials."	( Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Plosker, GL, 2014)	2.57
"Canagliflozin has been shown to increase the activity of the AMP-activated protein kinase (AMPK), a metabolic energy sensor important for increasing fatty acid oxidation and energy expenditure and suppressing lipogenesis and inflammation, but whether AMPK activation is important for mediating some of the beneficial metabolic effects of canagliflozin has not been determined."	( The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice. Day, EA; Desjardins, EM; Ford, RJ; Green, AE; Lally, JSV; Lu, JH; Lu, R; Lundenberg, L; Schertzer, JD; Steinberg, GR, 2020)	1.6
"Canagliflozin treatment has been shown to provide glycaemic improvements as well as reductions in blood pressure and body weight across a broad range of patients with T2DM, including those with elevated cardiovascular risk. "	( Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. Budoff, MJ; Wilding, JPH, 2017)	2.29
"Canagliflozin (CANA) has been shown to improve HbA1c, blood pressure (BP), and weight in patients with type 2 diabetes mellitus (T2DM) in clinical trials. "	( Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study. Chow, W; Duh, MS; Lafeuille, MH; Lefebvre, P; Pfeifer, M; Pilon, D; Robitaille, MN, 2016)	2.09
"Canagliflozin has been proposed as an effective treatment for type 2 diabetes. "	( Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials. Jiang, F; Liu, D; Meng, Q; Shen, Y, 2016)	2.26

Excerpt	Reference	Relevance
"Canagliflozin can inhibit SGLT-1 at therapeutic levels; however, the underlying molecular mechanism is not understood."	( Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function. Dasari, D; Dhar, A; Goyal, SG; Penmetsa, A; Sriram, D, 2023)	3.07
"Canagliflozin failed to produce an additive effect to improve beta cell glucose sensitivity above that observed with liraglutide."	( Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA1c with Cana and Lira in T2DM. Abdul-Ghani, M; Adams, J; Al-Jobori, H; Ali, AM; Cersosimo, E; DeFronzo, R; Mari, A; Martinez, R; Triplitt, C, 2020)	1.28
"Canagliflozin was shown to increase the risks of amputation and bone fracture compared with placebo when using the difference in RMST."	( Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio. Kaneko, M; Narukawa, M, 2019)	1.96
"Canagliflozin did not cause hypoglycemia, consistent with the RTG values remaining above the hypoglycemia threshold."	( Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. Arnolds, S; Demarest, K; Devineni, D; Ghosh, A; Hompesch, M; Morrow, L; Polidori, D; Rothenberg, P; Sha, S; Spitzer, H, 2014)	1.42
"Canagliflozin did not cause hypoglycemia, consistent with the RTG values remaining above the hypoglycemia threshold."	( Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. Arnolds, S; Demarest, K; Devineni, D; Ghosh, A; Hompesch, M; Morrow, L; Polidori, D; Rothenberg, P; Sha, S; Spitzer, H, 2014)	1.42

Excerpt	Reference	Relevance
"Canagliflozin treatment reduced KidneyIntelX risk scores over time and changes in the KidneyIntelX score from baseline to 1 year associated with future risk of DKD progression, independent of the baseline risk score and treatment arm."	( Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial. Coca, SG; Fleming, F; Hansen, MK; Heerspink, HJL; Lam, D; Mahaffey, KW; Mosoyan, G; Nadkarni, GN; Neal, B; Rosenthal, N, 2022)	1.44
"Canagliflozin treatment significantly increased plasma FFA and β-hydroxybutyrate regardless of background antihyperglycemic therapy."	( Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). Baldi, S; Ferrannini, E; Figtree, GA; Hansen, MK; Mahaffey, KW; Neal, B; Perkovic, V; Rosenthal, N; Scozzaro, T; Shaw, W; Tesfaye, F; Tsimihodimos, V, 2022)	1.68
"Canagliflozin treatment significantly reduced ALT, AST, and γGT over time."	( Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program. Ferrannini, E; Ferrannini, G; Hansen, MK; Rosenthal, N, 2022)	1.44
"Canagliflozin treatment significantly reduced high-salt-induced hypertension and this effect was not totally dependent on urinary sodium excretion in salt-sensitive hypertensive rats."	( Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt-Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling. Cao, T; Gao, P; He, C; Hu, Y; Li, L; Li, Q; Liu, D; Lu, Z; Luo, Z; Shu, W; Sun, F; Wang, L; Yan, Z; Zhang, H; Zhao, Y; Zhu, Z, 2022)	1.71
"Canagliflozin treatment significantly reduced insulin concentrations at week 24 (p < 0.001), and the between-group difference (canagliflozin minus glimepiride) in those changes was - 3.52 mU/L (95% confidence interval, - 4.85 to - 2.19; p < 0.001)."	( Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial. Ako, J; Imai, T; Node, K; Sezai, A; Shimabukuro, M; Taguchi, I; Tanaka, A; Toyoda, S; Watada, H, 2022)	1.64
"Canagliflozin treatment attenuated these changes."	( Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function. Dasari, D; Dhar, A; Goyal, SG; Penmetsa, A; Sriram, D, 2023)	3.07
"Canagliflozin treatment alone moderately inhibited mitochondrial oxidative phosphorylation and exhibited greater antiproliferative capacity than specific mitochondrial complex-I inhibitors."	( Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α. Abdulkarim, B; Ahmadi, E; Ali, A; Berg, T; Biziotis, OD; Bramson, JL; Ellis, P; Farrell, T; Mekhaeil, B; Menjolian, G; Mesci, A; Muti, P; Singh, K; Steinberg, GR; Sur, RK; Tsakiridis, EE; Tsakiridis, T; Wang, S; Wu, J, 2023)	3.07
"Canagliflozin treatment significantly reduced right ventricular systolic pressure and increased pulmonary acceleration time determined by hemodynamic assessments."	( Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation. Cai, Q; Chen, L; Li, X; Tang, L; Wang, X; Yang, Y, 2023)	3.07
"Canagliflozin treatment decreased fat mass and increased energy expenditure via increasing thermogenesis and lipolysis in adipose tissue."	( Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation. Chen, L; Cheng, S; Ding, Y; He, J; Huang, Y; Jiang, W; Li, R; Li, Y; Liu, Q; Pu, S; Shi, X; Tang, Q; Wang, R; Wu, T; Yang, X; Zhang, J; Zhang, Z; Zhao, Y; Zou, M, 2021)	1.59
"Canagliflozin treatment has been shown to provide glycaemic improvements as well as reductions in blood pressure and body weight across a broad range of patients with T2DM, including those with elevated cardiovascular risk. "	( Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. Budoff, MJ; Wilding, JPH, 2017)	2.29
"Canagliflozin treatment improved BG in DM mice by ~35%, but did not improve microarchitectural parameters."	( SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice. Clay Bunn, R; Cockrell, GE; Fowlkes, JL; Lumpkin, CK; Nyman, JS; Rettiganti, MR; Thrailkill, KM; Uppuganti, S; Wahl, EC, 2016)	1.16
"Canagliflozin treatment was associated with an increase in vaginal colonization with Candida species and in VVAE in women with T2DM."	( Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Nyirjesy, P; Usiskin, K; Ways, K; Zhao, Y, 2012)	2.03
"Canagliflozin treatment improved glycaemic control, reduced body weight and was generally well tolerated in subjects with T2DM inadequately controlled with diet and exercise."	( Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Alba, M; Canovatchel, W; Cefalu, WT; Kim, KA; Meininger, G; Stenlöf, K; Tong, C; Usiskin, K, 2013)	2.14
"Treatment with canagliflozin 1 mg/kg lowered RT(G) from 415±12 mg/dl to 94±10 mg/dl in ZDF rats while maintaining a threshold relationship between BG and UGE with virtually no UGE observed when BG was below RT(G). "	( Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. Arakawa, K; Conway, B; Conway, J; Demarest, K; Du, F; Kuriyama, C; Liang, Y; Liu, Y; Martin, T; Matsushita, Y; Polidori, D; Ueta, K; Ways, K; Xu, J, 2012)	1.13
"Treatment with canagliflozin increased the proportion of Th1 cells by 2.3 times, decreased the proportion of Th2 cells by 68.5%, and significantly restrained the synthesis of immunoglobulin G1 in B-cells and glomerulus subepithelial immune complex deposition."	( Canagliflozin reverses Th1/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy. Li, J; Lin, Y; Liu, H; Lv, X; Ma, G; Shao, X; Wang, J; Yu, P; Zhang, L; Zhou, S, 2022)	2.5
"Treatment with canagliflozin did not significantly change IGF-1 and IGFBP-3 concentrations by 3 years (p-value > 0.05)."	( Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial. Butler, J; Hansen, MK; Heerspink, HJL; Januzzi, JL; Jardine, M; Liu, Y; Masson, S; Mohebi, R; Pollock, CA; Sattar, N; Yavin, Y, 2023)	1.25
"Mice treated with canagliflozin were resistant to high-fat diet-induced obesity and its metabolic consequences. "	( Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation. Chen, L; Cheng, S; Ding, Y; He, J; Huang, Y; Jiang, W; Li, R; Li, Y; Liu, Q; Pu, S; Shi, X; Tang, Q; Wang, R; Wu, T; Yang, X; Zhang, J; Zhang, Z; Zhao, Y; Zou, M, 2021)	1.2
"Treatment with canagliflozin was associated with development of euglycemic ketoacidosis."	( ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin. Chan, P; Danford, C; Magill, SB, 2016)	1.01
"In untreated and canagliflozin-treated subjects, the relationship between UGE rate and BG was well described by a threshold relationship. "	( Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. Ghosh, A; Heise, T; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S, 2013)	0.94
"Treatment with canagliflozin for 12 weeks significantly improved glycaemic control and reduced body weight in Japanese patients with T2DM. "	( Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Inagaki, N; Kondo, K; Kuki, H; Maruyama, N; Susuta, Y; Yoshinari, T, 2013)	1.05
"Treatment with canagliflozin for 6 to 12 months improved model-based measures of beta cell function in three separate Phase 3 studies."	( Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Ferrannini, E; Mari, A; Polidori, D, 2014)	2.2
"Treatment with canagliflozin for 8 weeks from the prediabetic stage suppressed the progression of hyperglycemia, prevented the decrease in plasma insulin levels, increased pancreatic insulin contents, and minimized the deterioration of islet structure."	( Analysis of the effect of canagliflozin on renal glucose reabsorption and progression of hyperglycemia in zucker diabetic Fatty rats. Arakawa, K; Hikida, K; Kakimoto, T; Kimata, H; Kuriyama, C; Lee, SP; Matsushita, Y; Nakayama, K; Qi, J; Saito, A; Shiotani, M; Taniuchi, N; Ueta, K; Watanabe, Y; Xu, JZ, 2014)	1.04
"Treatment with canagliflozin was associated with an increased rate of genital mycotic infections (GMIs) and urinary tract infections (UTIs) in all racial groups."	( The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Alba, M; Davies, M; Davies, MJ; Gavin, JR; Meininger, G; Vijapurkar, U, 2015)	1.05
"Treatment with canagliflozin was effective and generally well tolerated in both women (and men) with T2DM."	( Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetes. Kushner, P, 2016)	1.02
"Treatment with canagliflozin significantly decreased adiposity and levels of fasting glucose and HbA1c but increased average serum FABP4 level by 10.3% (18.0 ± 1.0 vs."	( Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor. Furuhashi, M; Hiramitsu, S; Ishii, J; Matsumoto, M; Miura, T; Moniwa, N; Omori, A; Tanaka, M; Yoshida, H, 2016)	1.01
"Oral treatment with canagliflozin and TA-1887 also enhanced glucose-induced aGLP-1 elevation when co-administered with either teneligliptin or sitagliptin."	( Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents. Arakawa, K; Hikida, K; Kuriyama, C; Matsushita, Y; Minami, M; Nakayama, K; Oguma, T; Saito, A; Shiotani, M; Tsuda-Tsukimoto, M; Ueta, K, 2016)	0.75

Excerpt	Reference	Relevance
" Adverse events (AEs) were recorded throughout the study."	( Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Alba, M; Canovatchel, W; Cefalu, WT; Kim, KA; Meininger, G; Stenlöf, K; Tong, C; Usiskin, K, 2013)	0.7
" Safety was assessed based on adverse event (AE) reports; renal safety parameters (e."	( Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Meininger, G; Usiskin, K; Wajs, E; Xi, L; Yale, JF; Yue, D, 2013)	0.7
" Adverse events (AEs) were reported throughout the study."	( Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Bode, B; Fung, A; Stenlöf, K; Sullivan, D; Usiskin, K, 2013)	0.7
"The use of currently available antihyperglycemic agents can be limited by contraindications; cost; renal and hepatic dosage adjustments; dosing schedules; and adverse effects such as gastrointestinal upset, weight gain, and hypoglycemia."	( The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Harris, KB; Riser Taylor, S, 2013)	0.39
" The safety assessments included adverse events (AEs) and clinical laboratory tests."	( Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Inagaki, N; Kondo, K; Kuki, H; Maruyama, N; Susuta, Y; Yoshinari, T, 2013)	0.7
" 39 (8%) patients had serious adverse events in the glimepiride group versus 24 (5%) in the canagliflozin 100 mg group and 26 (5%) in the 300 mg group."	( Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH, 2013)	0.92
" Adverse events (AEs) were recorded throughout the study."	( Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C, 2013)	0.7
" Adverse events (AEs) were recorded throughout the study."	( Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Alba, M; Canovatchel, W; Cefalu, WT; Edwards, R; Jodar, E; Kim, KA; Meininger, G; Stenlöf, K; Tong, C, 2014)	0.68
" Overall adverse event (AE) rates were similar across groups over 52 weeks, with higher rates of genital mycotic infections and osmotic diuresis-related AEs seen with canagliflozin vs."	( Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP, 2013)	0.9
" The most common adverse effects are genital mycotic infections occurring in 11-15% of women exposed to canagliflozin versus 2-4% of those randomized to glimepiride or sitagliptin."	( Safety of canagliflozin in patients with type 2 diabetes. Mikhail, N, 2014)	1.02
" Overall adverse event (AE) incidence over 52 weeks was 69."	( Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J, 2014)	0.71
" Assessment of safety/tolerability included adverse event (AE) reports, incidence of documented hypoglycaemia, and percent change from baseline in fasting plasma lipids."	( Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Bode, B; Desai, M; Fung, A; Harris, S; Mayer, C; Meininger, G; Shaw, W; Sinclair, A; Usiskin, K; Vijapurkar, U, 2014)	0.71
" Adverse effects such as increased urinary frequency, genital mycotic infections, and urinary tract infections may discourage the use of CAN in the elderly patient."	( A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes. Baggett, S; Elmore, LK; Kyle, JA; Skelley, JW, 2014)	0.67
" Safety/tolerability evaluations included adverse event (AE) reporting, with additional data collection prespecified for selected AEs, and assessments of renal-related, lipid, and other safety laboratory parameters."	( Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Fung, A; Kline, I; Mayer, C; Meininger, G; Usiskin, K, 2014)	0.7
" Efficacy endpoints included changes in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight and systolic blood pressure (BP); adverse events (AEs) were also recorded."	( Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Bakris, G; Cariou, B; David-Neto, E; Figueroa, K; Jiang, J; Law, G; Meininger, G; Nieto, J; Usiskin, K; Wajs, E; Yale, JF; Yue, D, 2014)	0.71
" The most common adverse events with canagliflozin included genital mycotic infections and adverse events related to reduced intravascular volume likely secondary to osmotic diuresis."	( Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Bakris, G; Davies, M; de Zeeuw, D; Kline, I; Mayer, C; Meininger, G; Perkovic, V; Usiskin, K; Vijapurkar, U; Woo, V; Yamout, H, 2014)	0.99
" Common adverse effects including genital tract infections and osmotic diuresis-related AEs were identified and reviewed."	( Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Huang, YL; Lai, D; Shen, HP; Yang, XP; Zhong, XY, 2014)	0.71
"The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2 diabetes mellitus (T2DM; N=2313)."	( Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. Fung, A; Gilbert, RE; Januszewicz, A; Kline, I; Meininger, G; Vijapurkar, U; Weir, MR, 2014)	1.16
" The main adverse effects likely to be seen are a very small increase in risk of urinary tract infections and a modest risk of developing genital fungal infections."	( A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes. Boyle, LD; Wilding, JP, 2014)	0.71
" Safety was assessed by adverse event (AE) reports."	( Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Bode, B; Fung, A; Harris, S; Meininger, G; Stenlöf, K; Sullivan, D; Usiskin, K, 2015)	0.7
" No deaths, hypoglycemic events, or discontinuations due to adverse events were observed."	( Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. Chen, X; Curtin, CR; Devineni, D; Hu, P; Polidori, D; Sha, S; Stieltjes, H; Vaccaro, N; Weiner, S, 2015)	0.66
" Canagliflozin was generally safe and well tolerated in these healthy Chinese subjects."	( Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. Chen, X; Curtin, CR; Devineni, D; Hu, P; Polidori, D; Sha, S; Stieltjes, H; Vaccaro, N; Weiner, S, 2015)	1.57
" Safety/tolerability evaluation included reporting of general and prespecified adverse events (AEs)."	( The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Alba, M; Davies, M; Davies, MJ; Gavin, JR; Meininger, G; Vijapurkar, U, 2015)	0.71
" Canagliflozin was generally safe and well tolerated."	( The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Alba, M; Davies, M; Davies, MJ; Gavin, JR; Meininger, G; Vijapurkar, U, 2015)	1.62
" Safety was evaluated on the basis of adverse event (AE) reports, blood and urine laboratory parameters, and vital signs."	( Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Iijima, H; Inagaki, N; Kifuji, T; Maruyama, N, 2015)	0.67
" Higher incidences of genital mycotic infections and osmotic diuresis-related adverse events (AEs) were seen with canagliflozin compared with placebo."	( Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Capuano, G; de Zeeuw, D; Desai, M; Fulcher, G; Mahaffey, KW; Mathieu, C; Matthews, DR; Meininger, G; Neal, B; Perkovic, V; Shaw, W; Vercruysse, F; Woo, V; Wysham, C, 2016)	0.96
" Safety was assessed by adverse event (AE) reports."	( Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Alba, M; Henry, RR; Polidori, D; Thakkar, P; Tong, C, 2015)	0.73
" The effects of canagliflozin on the incidence of adverse events (AEs), BP, and LDL-C were evaluated."	( Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Goda, M; Iijima, H; Inagaki, N; Maruyama, N; Yokota, S, 2015)	0.98
" Safety was assessed based on adverse event (AE) reports."	( Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Alba, M; Cerdas, S; Chacon, Mdel P; Eliaschewitz, FG; Lavalle-González, FJ; Tong, C, 2016)	0.74
" Some manageable adverse events include genital mycotic infections, urinary tract infections, osmotic diuresis-related events etc."	( Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Agarwal, NB; Kaushal, N; Mali, G; Parveen, R; Raisuddin, S, 2016)	0.74
" Safety was assessed based on adverse event (AE) reports from eight randomized, double-blind, placebo- and active-controlled studies (N = 9,439; n = 8,949 aged <75, n = 490 aged ≥75)."	( Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. Bode, B; Desai, M; Harris, S; Meininger, G; Shaw, W; Sinclair, AJ; Vijapurkar, U, 2016)	0.74
" Safety was assessed by reports of adverse events."	( Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Desai, M; Fioretto, P; Gilbert, RE; Kline, I; Law, G; Meininger, G; Shaw, W; Weir, MR, 2016)	0.65
" The overall incidence of adverse events was similar across treatment groups regardless of sex, baseline BMI, baseline age or baseline eGFR."	( Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Desai, M; Fioretto, P; Gilbert, RE; Kline, I; Law, G; Meininger, G; Shaw, W; Weir, MR, 2016)	0.65
"Efficacy endpoints included change from baseline in HbA1c, body weight (BW), systolic blood pressure (SBP), and lipids at week 26; safety and tolerability were assessed by adverse event reports."	( Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity. Aguilar, R; Alba, M; Davidson, JA; Lavalle González, FJ; Meininger, G; Trujillo, A; Vijapurkar, U, 2016)	0.74
"6 mmol/l (≥100 mg/dl); and no volume depletion-related adverse events (AEs) within 2 weeks before dose increase."	( Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Aggarwal, N; Alba, M; Cao, A; Fung, A; Pfeifer, M; Rodbard, HW; Seufert, J, 2016)	0.72
" The overall incidence of adverse events was similar between the two groups."	( Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Goda, M; Harashima, S; Iijima, H; Inagaki, N; Kawaguchi, Y; Maruyama, N, 2016)	0.74
"The safety profile of SGLT2 inhibitors is well defined, and the adverse event profile is largely consistent with their mechanism of action."	( Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus. Carlson, CJ; Santamarina, ML, 2016)	0.43
" The overall safety of canagliflozin was good, with the exception of high incidence of genital mycotic infections and osmotic diuresis-related adverse events."	( Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Chang, F; Xiao, MY; Xiong, W; Zhang, M, 2016)	1.06
" Safety was assessed based on adverse event (AE) reports, including the incidence of AEs related to the mechanism of SGLT2 inhibition."	( Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Balis, D; Davies, MJ; Desai, M; Meininger, G; Qiu, R; Xie, J, 2017)	0.72
"The incidence of renal-related adverse events (AEs) with canagliflozin in patients with type 2 diabetes mellitus from a pooled population of patients in 7 active- and placebo-controlled trials (N = 5598) and in a 104-week study vs glimepiride (N = 1450) was low and similar in canagliflozin and non-canagliflozin groups."	( Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Balis, D; Canovatchel, W; Desai, M; Rosenthal, N; Sun, D; Xie, J; Yavin, Y, 2017)	1.05
" Other endpoints included changes in fasting plasma glucose, body weight, proinsulin/C-peptide ratio, homeostatic model assessment 2-%B and adverse events."	( Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Gouda, M; Iijima, H; Inagaki, N; Kadowaki, T; Kaneko, G; Kondo, K; Maruyama, N; Nakanishi, N; Nishimura, K; Watanabe, Y, 2017)	0.77
" Safety was assessed based on adverse event (AE) reports."	( Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Davies, MJ; Merton, K; Qiu, R; Vijapurkar, U; Yee, J, 2017)	0.77
" The safety endpoint was the incidence of adverse events (AEs)."	( Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes. Gouda, M; Iijima, H; Inagaki, N; Kadowaki, T; Kaneko, G; Kondo, K; Maruyama, N; Nakanishi, N; Nishimura, K; Watanabe, Y, 2018)	0.76
" The incidence of adverse events was similar in both groups (55."	( Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study. Gouda, M; Iijima, H; Inagaki, N; Kadowaki, T; Kaneko, G; Kondo, K; Maruyama, N; Nakanishi, N; Nishimura, K; Watanabe, Y, 2018)	0.74
" The main outcomes included the incidences of adverse drug reactions (ADRs), serious ADRs, and the changes of laboratory tests as well as efficacy variables."	( Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan. Goda, M; Sasaki, K; Tajima, T; Ueno, M; Yamakura, T, 2018)	0.79
" The safety endpoints were adverse events, hypoglycaemic events, and laboratory test values."	( Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Harashima, SI; Iijima, H; Inagaki, N; Kaku, K; Kawaguchi, Y; Kondo, K; Maruyama, N; Otsuka, M, 2018)	0.76
" Adverse events occurred in 85."	( Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Harashima, SI; Iijima, H; Inagaki, N; Kaku, K; Kawaguchi, Y; Kondo, K; Maruyama, N; Otsuka, M, 2018)	0.76
" Our discovery of canagliflozin-mediated simultaneous inhibition of GDH and ETC complex I in renal cells at clinically relevant concentrations, and their particular susceptibility to necrotic cell death during proliferation, provides a mechanistic rationale for the adverse effects observed especially in patients with preexisting chronic kidney disease or previous kidney injury characterized by sustained regenerative tubular epithelial cell proliferation."	( Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect. Beneke, S; Delp, J; Dietrich, DR; Gutbier, S; Leist, M; Schlichenmaier, N; Secker, PF, 2018)	2.26
" Safety endpoints included adverse events (AEs), hypoglycaemia and laboratory tests."	( Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study. Harashima, SI; Inagaki, N; Kawaguchi, Y; Kondo, K; Maruyama, N; Otsuka, M; Watanabe, Y, 2018)	0.79
"To assess the association between the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and seven serious adverse events of current concern."	( Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P, 2018)	0.48
"In this analysis of nationwide registers from two countries, use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was associated with an increased risk of lower limb amputation and diabetic ketoacidosis, but not with other serious adverse events of current concern."	( Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. Eliasson, B; Franzén, S; Gudbjörnsdottir, S; Hveem, K; Jonasson, C; Melbye, M; Pasternak, B; Svanström, H; Svensson, AM; Ueda, P, 2018)	0.48
" However, wide CIs for many comparisons suggest limited precision, and therefore clinically important adverse events cannot be ruled out."	( Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. Aubrey-Bassler, K; Chibrikov, E; Curnew, D; Donnan, JR; Gamble, JM; Grandy, CA; Hache, J; Johnston, K; Marra, CA; Nguyen, H; Swab, M, 2019)	0.51
" Whereas, several adverse events caused by SGLT2is were also reported."	( Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus. Abe, I; Abe, M; Fujii, H; Kobayashi, K; Kudo, T; Minezaki, M; Mukoubara, S; Ochi, K; Ohe, K; Ohishi, H; Ohnishi, Y; Shinagawa, T; Sugimoto, K; Takashi, Y; Yamao, Y, 2019)	0.72
" A total of 9 adverse events were reported including 2 episodes of urinary tract infection (UTI) and 4 episodes of genital infection."	( Real world study of short term efficacy, safety, and tolerability of canagliflozin 100 mg initiation in type 2 diabetes mellitus patients during hot humid Indian summer. Ghosh, S; Majumder, A; Pandit, K; Sanyal, D, )	0.37
" This analysis of CREDENCE trial data examines the effect of canagliflozin on the incidence of kidney-related adverse events (AEs)."	( Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. Agarwal, R; Capuano, G; Charytan, DM; Craig, J; de Zeeuw, D; Di Tanna, GL; Heerspink, HJL; Jardine, MJ; Levin, A; Li, J; Neal, B; Oshima, M; Perkovic, V; Wheeler, DC; Yavin, Y; Zhang, H, 2022)	2.41
" These results highlight the safety of canagliflozin with regard to adverse kidney-related AEs."	( Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. Agarwal, R; Capuano, G; Charytan, DM; Craig, J; de Zeeuw, D; Di Tanna, GL; Heerspink, HJL; Jardine, MJ; Levin, A; Li, J; Neal, B; Oshima, M; Perkovic, V; Wheeler, DC; Yavin, Y; Zhang, H, 2022)	2.43
"Clinical trials are often underpowered to detect serious but rare adverse events of a new medication."	( A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. Fralick, M; Kulldorff, M; Patorno, E; Redelmeier, D; Schneeweiss, S; Vine, S; Wang, SV, 2021)	0.62
" We screened for incident adverse events where there were more outcomes observed among canagliflozin vs."	( A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. Fralick, M; Kulldorff, M; Patorno, E; Redelmeier, D; Schneeweiss, S; Vine, S; Wang, SV, 2021)	0.84
"In a large population-based study, we identified known but no other adverse events associated with canagliflozin, providing reassurance on its safety among adult patients with T2D and suggesting the tree-based scan statistic method is a useful post-marketing safety monitoring tool for newly approved medications."	( A novel data mining application to detect safety signals for newly approved medications in routine care of patients with diabetes. Fralick, M; Kulldorff, M; Patorno, E; Redelmeier, D; Schneeweiss, S; Vine, S; Wang, SV, 2021)	0.84
" Safety was evaluated in terms of adverse drug reactions (ADRs)."	( Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance. Hamada, K; Inagaki, N; Iwasaki, T; Mori-Anai, K; Nangaku, M; Sakata, Y; Sasaki, K, 2022)	0.99
" Adverse drug reactions occurred in 10."	( Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance. Hamada, K; Inagaki, N; Iwasaki, T; Mori-Anai, K; Nangaku, M; Sakata, Y; Sasaki, K, 2022)	0.99
" Compared with controls, empagliflozin 10 mg and 25 mg, and canagliflozin 100 mg reduced the risk of any adverse events while canagliflozin 100 mg reduced the risk of serious adverse events."	( Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: a network meta-analysis and systematic review. Lin, J; Wang, S; Wen, T; Zhang, X, 2022)	0.96
"5%) discontinued treatment due to adverse events which were SGLT2i related."	( SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Berra, C; Bertuzzi, F; Betella, N; Bucciarelli, L; Bulgheroni, M; Cimino, V; Favacchio, G; Fiorina, P; Folli, F; Gandolfi, A; Girelli, A; Lunati, ME; Luzi, L; Mascardi, C; Massari, G; Mirani, M; Montefusco, L; Morpurgo, PS; Pace, C; Pastore, I; Pintaudi, B; Trevisan, M, 2022)	0.72
"SGLT2i are well-tolerated and safe in the elderly and appear as an effective therapeutic option, though some caution is also suggested, especially in more fragile subjects."	( SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Berra, C; Bertuzzi, F; Betella, N; Bucciarelli, L; Bulgheroni, M; Cimino, V; Favacchio, G; Fiorina, P; Folli, F; Gandolfi, A; Girelli, A; Lunati, ME; Luzi, L; Mascardi, C; Massari, G; Mirani, M; Montefusco, L; Morpurgo, PS; Pace, C; Pastore, I; Pintaudi, B; Trevisan, M, 2022)	0.72
" Canagliflozin has one reported major degradation product, also metformin hydrochloride has one reported major degradation product, cyanoguanidine, and has a potential toxic impurity, melamine, that is reported to cause crystalluria that causes chronic kidney inflammation and nephrolithiasis leading to a renal failure."	( Ecofriendly appraisal of stability-indicating high-performance chromatographic assay of canagliflozin and metformin with their toxic impurities; in silico toxicity prediction. Emam, AA; Emam, RA, 2023)	2.04

Excerpt	Reference	Relevance
" Half-life and time at which Cmax was observed were dose-independent."	( Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. Curtin, CR; Devineni, D; Gutierrez, MJ; Murphy, J; Polidori, D; Rothenberg, PL; Rusch, S, 2013)	0.66
"An extensive literature search was performed to analyze the pharmacokinetic characteristics, toxicological issues and safety concerns of SGLT2 inhibitors in humans."	( Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Scheen, AJ, 2014)	0.4
"The three pharmacological agents share an excellent oral bioavailability, long half-life allowing once-daily administration, low accumulation index and renal clearance, the absence of active metabolites and a limited propensity to drug-drug interactions."	( Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Scheen, AJ, 2014)	0.4
"This study evaluated the effects of HCTZ on the pharmacokinetic and pharmacodynamic properties and tolerability of canagliflozin in healthy participants."	( Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Devineni, D; Polidori, D; Rusch, S; Vaccaro, N; Wajs, E, 2014)	0.83
" Blood samples were taken before and several times after administration on day 7 of period 1 and on days 28 and 35 of period 2 for canagliflozin and HCTZ pharmacokinetic analyses using LC-MS/MS."	( Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Devineni, D; Polidori, D; Rusch, S; Vaccaro, N; Wajs, E, 2014)	0.83
"Adding canagliflozin treatment to healthy participants on HCTZ treatment had no notable pharmacokinetic or pharmacodynamic effects; canagliflozin coadministered with HCTZ was generally well tolerated, with no unexpected tolerability concerns."	( Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Devineni, D; Polidori, D; Rusch, S; Vaccaro, N; Wajs, E, 2014)	1.08
" Pharmacodynamic parameters were assessed at baseline and at weeks 1 and 12."	( Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS, 2014)	0.65
"This randomized, double-blind, placebo-controlled, single and multiple ascending-dose study evaluated the pharmacodynamic effects and safety/tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes."	( Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. Arnolds, S; Demarest, K; Devineni, D; Ghosh, A; Hompesch, M; Morrow, L; Polidori, D; Rothenberg, P; Sha, S; Spitzer, H, 2014)	0.9
"This randomized, double-blind, placebo-controlled, single and multiple ascending-dose study evaluated the pharmacodynamic effects and safety/tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes."	( Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. Arnolds, S; Demarest, K; Devineni, D; Ghosh, A; Hompesch, M; Morrow, L; Polidori, D; Rothenberg, P; Sha, S; Spitzer, H, 2014)	0.9
" Probenecid increased the Cmax by 13% and the AUC by 21%."	( Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Ariyawansa, J; Curtin, C; Devineni, D; Di Prospero, NA; Mamidi, RN; Murphy, J; Rothenberg, P; Stieltjes, H; Vaccaro, N; Wajs, E; Wang, SS; Weiner, S, 2015)	0.64
"To compare the pharmacodynamic effects of the highest approved doses of the sodium glucose co-transporter 2 (SGLT2) inhibitors canagliflozin and dapagliflozin on urinary glucose excretion (UGE), renal threshold for glucose excretion (RTG ) and postprandial plasma glucose (PPG) excursion in healthy participants in a randomized, double-blind, two-period crossover study."	( Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Farrell, K; Ghosh, A; Natarajan, J; Pinheiro, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Vaccaro, N, 2015)	0.9
" The available SGLT2 inhibitors share similar pharmacokinetic characteristics, with a rapid oral absorption, a long elimination half-life allowing once-daily administration, an extensive hepatic metabolism mainly via glucuronidation to inactive metabolites, the absence of clinically relevant drug-drug interactions and a low renal elimination as parent drug."	( Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen, AJ, 2015)	0.42
" Similarly, pharmacodynamic effects of canagliflozin on RTG and UGE were found to be dose- and concentration-dependent."	( Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Devineni, D; Polidori, D; Stieltjes, H; Vaccaro, N; Wajs, E, 2015)	0.92
"When comparing the IR FDC tablet administered with and without food, PK parameters of canagliflozin were bioequivalent as the 90% confidence intervals (CIs) for log-transformed AUClast, AUCâ, and Cmax were within the bioequivalence limits of 80-125%."	( Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants. Devineni, D; Murphy, J; Stieltjes, H; Wajs, E; Wang, SS, 2015)	0.9
" The Cmax of metformin was decreased by 16%, which is not considered clinically meaningful."	( Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants. Devineni, D; Murphy, J; Stieltjes, H; Wajs, E; Wang, SS, 2015)	0.68
" In the renal study, the mean Cmax values were 13%, 29%, and 29% higher and the mean AUC0-∞ values were 17%, 63%, and 50% higher in participants with mild, moderate, and severe renal impairment, respectively; values were similar in the ESRD group relative to the group with normal function, however."	( Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curtin, CR; Devineni, D; Marbury, TC; Rusch, S; Smith, W; Stieltjes, H; Vaccaro, N; Vandebosch, A; Wajs, E; Wexler, D, 2015)	0.65
" Pharmacodynamic response to canagliflozin, measured by using UGE and RTG, declined with increasing severity of renal impairment."	( Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curtin, CR; Devineni, D; Marbury, TC; Rusch, S; Smith, W; Stieltjes, H; Vaccaro, N; Vandebosch, A; Wajs, E; Wexler, D, 2015)	0.95
" These SGLT2 inhibitors share similar pharmacokinetic characteristics with a rapid oral absorption, a long elimination half-life allowing once-daily administration, an extensive hepatic metabolism mainly via glucuronidation to inactive metabolites and a low renal elimination as a parent drug."	( Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Scheen, AJ, 2015)	0.42
" The pharmacokinetic findings in participants carrying the UGT1A93 and UGT2B42 allele implicate that UGT1A9 and UGT2B4 are involved in the metabolism of canagliflozin to M7 and M5, respectively."	( In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. Devineni, D; Favis, R; Francke, S; Jadwin, A; Mamidi, RN; Scheers, E; Solanki, B, 2015)	0.93
" Median tmax and mean t1/2 were independent of dose and regimen."	( Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Curtin, CR; Devineni, D; Murphy, J; Polidori, D; Stieltjes, H; Wajs, E; Wang, SS, 2015)	0.64
" The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10."	( Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Devineni, D; Polidori, D, 2015)	0.92
" Mean AUC and Cmax of canagliflozin increased in a dose-dependent manner after single-dose administration (AUC0-∞, 10,521 ng · h/mL for 100 mg, 33,583 ng · h/mL for 300 mg; Cmax, 1178 ng/mL for 100 mg, 4113 ng/mL for 300 mg)."	( Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. Chen, X; Curtin, CR; Devineni, D; Hu, P; Polidori, D; Sha, S; Stieltjes, H; Vaccaro, N; Weiner, S, 2015)	0.97
" Tmax and t½ of canagliflozin were independent of the dose."	( Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects. Chen, X; Curtin, CR; Devineni, D; Hu, P; Polidori, D; Sha, S; Stieltjes, H; Vaccaro, N; Weiner, S, 2015)	1
"The computational effort required to fit the pharmacodynamic (PD) part of a pharmacokinetic/pharmacodynamic (PK/PD) model can be considerable if the differential equations describing the model are solved numerically."	( The method of averaging applied to pharmacokinetic/pharmacodynamic indirect response models. de Winter, W; Dunne, A; Hsu, CH; Mariam, S; Neyens, M; Pinheiro, J; Woot de Trixhe, X, 2015)	0.42
"0 h and elimination half-life (t 1/2) of 10."	( Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Iijima, H; Inagaki, N; Kifuji, T; Maruyama, N, 2015)	0.67
" A population pharmacokinetic (popPK) model of canagliflozin, including relevant covariates as sources of inter-individual variability, was developed to describe phase I, II, and III data in healthy volunteers and in patients with type 2 diabetes mellitus (T2DM)."	( Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. De Winter, W; Devineni, D; Dunne, A; Hoeben, E; Neyens, M; Vermeulen, A, 2016)	0.96
" This study assessed the pharmacokinetic (PK) and pharmacodynamic (PD) properties and tolerability of single-dose canagliflozin 200 or 300 mg in healthy Indian participants."	( Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. Curtin, C; Devineni, D; Polidori, D; Stieltjes, H; Tian, H; Wajs, E, 2016)	0.89
" After the administration of single doses of 200 and 300 mg, the mean (SD) Cmax values were 1792 (430) ng/mL and 2789 (941) ng/mL, respectively; AUC0-∞, values were 18,706 (3818) ng·h/mL and 28,207 (5901) ng·h/mL, respectively."	( Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. Curtin, C; Devineni, D; Polidori, D; Stieltjes, H; Tian, H; Wajs, E, 2016)	0.68
" The Tmax and t½ of canagliflozin appeared to be independent of dose."	( Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. Curtin, C; Devineni, D; Polidori, D; Stieltjes, H; Tian, H; Wajs, E, 2016)	1.01
" Duration and onset of the pharmacologic effects seemed to be closely correlated with the pharmacokinetic properties of each SGLT2 inhibitor, particularly with respect to high distribution and long retention in the target organ, the kidney."	( Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M, 2016)	0.43
"1 mL) was established and applied to a pharmacokinetic study in rats."	( A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. Ito, Y; Kobuchi, S; Sakaeda, T; Yano, K, 2016)	0.68
"93) and Cmax (ratio: 108."	( Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants. Ariyawansa, J; Devineni, D; Di Prospero, NA; Manitpisitkul, P; Murphy, J; Rothenberg, P; Stieltjes, H, 2015)	0.68
" Pharmacokinetic parameters were assessed at prespecified intervals."	( Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants. Devineni, D; Mamidi, RN; Manitpisitkul, P; Murphy, J; Skee, D; Stieltjes, H; Tian, H; Usiskin, K; Vandebosch, A; Verhaeghe, T; Wajs, E; Wang, SS, )	0.53
" Therefore, a physiologically based pharmacokinetic (PBPK) model of canagliflozin was developed based on clinical data from healthy volunteers and it was used to simulate luminal concentrations in intestines and renal tubules."	( Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules. Mori, K; Nakamaru, Y; Saito, R; Shimizu, M; Yamazaki, H, 2016)	0.87
" A physiologically-based pharmacokinetic (PBPK) model was developed and clinical DDI simulations were performed to determine the likelihood of cytochrome P450 (CYP) inhibition by canagliflozin."	( In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Cuyckens, F; Dallas, S; Evans, DC; Johnson, MD; Kelley, MF; Leclercq, L; Lim, HK; Mamidi, RNVS; Scheers, E; Sensenhauser, C; Snoeys, J; Verboven, P, 2017)	0.86
"This study was conducted to evaluate the pharmacokinetic properties and bioequivalence of two oral formulations of canagliflozin: a newly developed generic formulation (test) and a branded formulation (reference)."	( Pharmacokinetics and bioequivalence of two oral formulations of canagliflozin after single-dose administration in healthy Chinese subjects . Hu, W; Liu, Z; Lu, C; Yang, Y; Zhang, Q; Zhou, R, 2020)	1.01
"To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of rongliflozin in a cohort of healthy Chinese people and people with type 2 diabetes mellitus (T2DM)."	( Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus. Chen, H; Ding, Y; Li, C; Li, X; Liu, C; Liu, J; Wu, M; Zhang, H; Zhang, Y; Zhu, X, 2020)	0.56
" This Phase I trial evaluated the pharmacokinetic and pharmacodynamic properties of DJT1116PG at steady state in healthy Chinese individuals."	( A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State. Chen, H; Ding, Y; Li, C; Li, X; Liu, J; Wu, M; Zhang, H; Zhu, X, 2020)	0.56
"A novel, selective and sensitive method is developed for simultaneous estimation of canagliflozin and metformin and successfully applied to fast and fed pharmacokinetic studies in healthy Indian volunteers."	( Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions. Gujar, S; Mungantiwar, A; Pandita, N; Wattamwar, T, 2020)	1.02
" The main pharmacokinetic parameters were calculated using the non-compartmental model."	( Evaluation of influence of telmisartan on the pharmacokinetics and tissue distribution of canagliflozin in rats and mice. Ding, CY; Dong, ZJ; Li, Y; Meng, L; Wang, XN, 2021)	0.84
"A pharmacokinetic drug-drug interaction between telmisartan and canagliflozin might occur during drug co-administration."	( Evaluation of influence of telmisartan on the pharmacokinetics and tissue distribution of canagliflozin in rats and mice. Ding, CY; Dong, ZJ; Li, Y; Meng, L; Wang, XN, 2021)	1.08
" Here, we developed an ultra-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of canagliflozin, sorafenib, and lenvatinib, and investigated the pharmacokinetic drug interactions between canagliflozin and sorafenib or lenvatinib in rats."	( Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats. Cui, Y; Dong, Z; Guo, C; Li, Y; Ma, Y, 2022)	1.2
" Tadalafil and canagliflozin were determined simultaneously in real human plasma using the described procedure and the method was applied for in vivo pharmacokinetic drug interaction study between the studied drugs, which proved significant interaction between them when administered simultaneously."	( Cytochrome P450 3A4-mediated pharmacokinetic interaction study between tadalafil and canagliflozin using high-performance thin-layer chromatography. Abdel-Aal, FAM; Ali, ABH; Mohamed, AI; Rageh, AH, 2022)	1.3
" This study aimed to evaluate donafenib-dapagliflozin and donafenib-canagliflozin pharmacokinetic interactions and explore the potential mechanisms."	( In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats. Dong, Z; Fu, Y; Guo, C; He, X; Li, Y; Wang, Z; Xun, X, 2023)	1.36

Excerpt	Reference	Relevance
"To evaluate the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin or metformin in combination with sulphonylurea."	( Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Dieu Van, NK; Han, P; Ji, L; Liu, Y; Meininger, G; Qiu, R; Vijapurkar, U; Yang, G, 2015)	2.13
"Canagliflozin provided glycaemic improvements and reductions in body weight and systolic BP, and was generally well tolerated in Asian patients with T2DM on metformin or metformin in combination with sulphonylurea."	( Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Dieu Van, NK; Han, P; Ji, L; Liu, Y; Meininger, G; Qiu, R; Vijapurkar, U; Yang, G, 2015)	3.3
" Since the sodium-glucose cotransporter 2 inhibitors share common structural features, notably a glycoside moiety, investigation of drugs in this class for effects on UGT to identify (or exclude) potential drug-drug interactions is warranted."	( Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions. Chau, N; Miners, JO; Pattanawongsa, A; Rowland, A, 2015)	0.66
"Canagliflozin in combination with insulin was effective in improving glycemic control and reducing body weight and well tolerated by Japanese patients with T2DM."	( Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Goda, M; Harashima, S; Iijima, H; Inagaki, N; Kawaguchi, Y; Maruyama, N, 2016)	2.19
" This meta-analysis of randomized control trials aimed to evaluate the effect of canagliflozin combined with other hypoglycemic drugs."	( Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials. Jiang, F; Liu, D; Meng, Q; Shen, Y, 2016)	1.04
"gov for randomized control trials comparing canagliflozin combined with conventional antidiabetic drugs vs placebo."	( Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials. Jiang, F; Liu, D; Meng, Q; Shen, Y, 2016)	1.07
" The potential for canagliflozin to cause clinical drug-drug interactions (DDIs) was assessed."	( In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Cuyckens, F; Dallas, S; Evans, DC; Johnson, MD; Kelley, MF; Leclercq, L; Lim, HK; Mamidi, RNVS; Scheers, E; Sensenhauser, C; Snoeys, J; Verboven, P, 2017)	1
"This study demonstrates the long-term efficacy and safety of canagliflozin combined with insulin in Japanese patients."	( Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Harashima, SI; Iijima, H; Inagaki, N; Kaku, K; Kawaguchi, Y; Kondo, K; Maruyama, N; Otsuka, M, 2018)	1
"To analyze the efficacy and safety of replacing sitagliptin with canagliflozin in patients with type 2 diabetes (T2D) and poor metabolic control despite treatment with sitagliptin in combination with metformin and/or gliclazide."	( Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study. Garcia de Lucas, MD; Gómez Huelgas, R; Olalla Sierra, J; Pérez Belmonte, LM; Suárez Tembra, M, 2018)	0.97
"5%) treated with sitagliptin in combination with metformin and/or gliclazide, sitagliptin (and gliclazide if appropriate) were replaced by canagliflozin."	( Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study. Garcia de Lucas, MD; Gómez Huelgas, R; Olalla Sierra, J; Pérez Belmonte, LM; Suárez Tembra, M, 2018)	0.94
"In patients with T2D poorly controlled with sitagliptin, whether alone or in combination with metformin and/or gliclazide, replacing it with canagliflozin may be a simple yet effective intensification strategy."	( Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study. Garcia de Lucas, MD; Gómez Huelgas, R; Olalla Sierra, J; Pérez Belmonte, LM; Suárez Tembra, M, 2018)	0.94
"Sodium-glucose cotransporter 2 inhibitor combined with dipeptidyl peptidase-4 inhibitor improved the quality of glycemic variability and reduced postprandial hyperglycemia compared with each monotherapy."	( Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study. Aoki, S; Atsumi, T; Cho, KY; Kameda, H; Kawata, S; Kurihara, Y; Miya, A; Miyoshi, H; Nagai, S; Nakamura, A; Nishimoto, N; Nomoto, H; Omori, K; Shigesawa, I; Sugawara, H; Takeuchi, J; Taneda, S; Tsuchida, K; Yanagiya, S; Yokoyama, H, 2021)	0.86
" We provide a comprehensive overview of the available pharmacological and clinical evidence on this potential drug-drug interaction (DDI)."	( Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence. Douros, A; Kontogiorgis, C; Lalagkas, PN; Poulentzas, G, 2021)	0.62
"Information on controlled trials was retrieved from four databases to obtain the effects of different doses of canagliflozin combined with metformin for treating T2DM."	( Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis. Li, G; Ni, J; Wang, S; Zhang, D, 2023)	1.39
"The meta-analysis demonstrates that high doses of canagliflozin combined with metformin may be potentially effective in patients with T2DM, as evidenced by LS means of HbA1c and FPG, and the above conclusions need to be verified by more high-quality studies."	( Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis. Li, G; Ni, J; Wang, S; Zhang, D, 2023)	1.43
" The diabetes drug canagliflozin inhibits NSCLC cell proliferation and the mammalian target of rapamycin (mTOR) pathway, which mediates cell growth and survival, but it is unclear whether this drug can enhance response rates when combined with cytotoxic therapy."	( Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α. Abdulkarim, B; Ahmadi, E; Ali, A; Berg, T; Biziotis, OD; Bramson, JL; Ellis, P; Farrell, T; Mekhaeil, B; Menjolian, G; Mesci, A; Muti, P; Singh, K; Steinberg, GR; Sur, RK; Tsakiridis, EE; Tsakiridis, T; Wang, S; Wu, J, 2023)	2.68

Excerpt	Reference	Relevance
" Canagliflozin has dose-dependent pharmacokinetics, and research in laboratory animals demonstrated high oral bioavailability (85%) and rapid effects in lowering glycosylated hemoglobin (HbA(1c)) values."	( Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. Kolanczyk, DM; Nisly, SA; Walton, AM, 2013)	2.74
"Food did not affect canagliflozin bioavailability parameters (Cmax and AUCs) or AUCs of metformin."	( Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants. Devineni, D; Murphy, J; Stieltjes, H; Wajs, E; Wang, SS, 2015)	1
" Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %."	( Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Devineni, D; Polidori, D, 2015)	0.91
" Sex, age, and weight on apparent volume of distribution of the central compartment, body mass index on first-order absorption rate constant, and body mass index and over-encapsulation on lag-time, and estimated glomerular filtration rate (eGFR, by MDRD equation), dose, and genetic polymorphism (carriers of UGT1A9*3 allele) on elimination rate constant were identified as statistically significant covariates."	( Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. De Winter, W; Devineni, D; Dunne, A; Hoeben, E; Neyens, M; Vermeulen, A, 2016)	0.7
"Absolute oral bioavailability of canagliflozin was assessed by simultaneous oral administration with intravenous [(14) C]-canagliflozin microdose infusion in nine healthy men."	( Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. Devineni, D; Mamidi, RN; Murphy, J; Rothenberg, P; Scheers, E; Stieltjes, H; Wang, SS, 2015)	0.95
"Canagliflozin (Invokana, JNJ-28431754) is an orally bioavailable and selective SGLT2 (subtype 2 sodium-glucose transport protein) inhibitor approved for the treatment of type 2 diabetes."	( Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin (JNJ-28431754). Hoerr, DC; Lin, R; Salter, R; Weaner, LE, 2017)	2.16
"The aim of the present investigation entails the development of solid SMEDDS for improving the oral bioavailability of canagliflozin using porous carriers."	( Role of Porous Carriers in the Biopharmaceutical Performance of Solid SMEDDS of Canagliflozin. Bedi, N; Singh, D; Tiwary, AK, 2018)	0.92
" Enhanced in vitro dissolution rate of optimized solid SMEDDS manifested in bioavailability enhancement of 167."	( Role of Porous Carriers in the Biopharmaceutical Performance of Solid SMEDDS of Canagliflozin. Bedi, N; Singh, D; Tiwary, AK, 2018)	0.71
"The present investigation reveals the immense potential of solid SMEDDS in augmenting the oral bioavailability profile of poorly water-soluble drug canagliflozin."	( Role of Porous Carriers in the Biopharmaceutical Performance of Solid SMEDDS of Canagliflozin. Bedi, N; Singh, D; Tiwary, AK, 2018)	0.91
" The current study entails development and evaluation of spray dried lipid based formulation (solid SMEDDS) for enhancing oral bioavailability and anti-diabetic activity of CFZ."	( Enhanced oral bioavailability and anti-diabetic activity of canagliflozin through a spray dried lipid based oral delivery: a novel paradigm. Arora, S; Bedi, N; Kesavan, AK; Singh, AP; Singh, D; Tiwary, AK, 2020)	0.8
" Graphical abstract Graphical Abstract: Enhanced oral bioavailability and anti-diabetic activity of canagliflozin through a spray dried lipid based oral delivery: a novel paradigm."	( Enhanced oral bioavailability and anti-diabetic activity of canagliflozin through a spray dried lipid based oral delivery: a novel paradigm. Arora, S; Bedi, N; Kesavan, AK; Singh, AP; Singh, D; Tiwary, AK, 2020)	1.02
"The present investigation attempts to optimize Supersaturable lipid based formulation (SS SMEDDS) of Biopharmaceutical Classification System (BCS) class IV drug canagliflozin (CFZ) and evaluating the oral bioavailability of the formulation."	( Polymeric Precipitation Inhibitor Based Supersaturable Self-microemulsifying Drug Delivery System of Canagliflozin: Optimization and Evaluation. Bedi, N; Kang, TS; Singh, D; Tiwary, AK, 2021)	1.03
" Canagliflozin reduced NADPH oxidase activity via AMP kinase (AMPK)/Rac1signalling and improved NOS coupling via increased tetrahydrobiopterin bioavailability ex vivo and in vitro."	( Effects of canagliflozin on human myocardial redox signalling: clinical implications. Akawi, N; Akoumianakis, I; Antoniades, C; Antonopoulos, AS; Badi, I; Carena, MC; Casadei, B; Channon, KM; Chuaiphichai, S; Farid, S; Kondo, H; Kotanidis, CP; Krasopoulos, G; Oikonomou, EK; Polkinghorne, M; Reus, EM; Sayeed, R; Shirodaria, C; Sommariva, E; Srivastava, V; Stadiotti, I, 2021)	1.92
" The purpose of this study is to transform the structure of berberine in order to improve the bioavailability of berberine and reduce the dosage."	( Synthesis of Berberine and Canagliflozin Chimera and Investigation into New Antibacterial Activity and Mechanisms. Che, S; Chen, Y; Hao, W; Li, J; Luo, J; Wei, H; Xie, W; Zhang, W; Zhao, Z, 2022)	1.02
" Commercially available CFZ tablets' active pharmaceutical ingredient (API) was Hemi-CFZ, which was easy conversion to CFZ or Mono-CFZ under the influence of temperature, pressure, humidity and other factors in tablets processing, storage, and transportation, thus affected bioavailability and efficacy of tablets."	( Quantitative analysis of low content polymorphic impurities in canagliflozin tablets by PXRD, NIR, ATR-FITR and Raman solid-state analysis techniques combined with stoichiometry. Gong, J; Li, H; Liu, J; Liu, M; Song, P; Wang, Q; Wu, S, 2023)	1.15

Excerpt	Relevance	Reference
" The observed pharmacokinetic/pharmacodynamic profile of canagliflozin in subjects with type 2 diabetes supports a once-daily dosing regimen."	( Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. Curtin, CR; Devineni, D; Gutierrez, MJ; Murphy, J; Polidori, D; Rothenberg, PL; Rusch, S, 2013)	0.9
"The use of currently available antihyperglycemic agents can be limited by contraindications; cost; renal and hepatic dosage adjustments; dosing schedules; and adverse effects such as gastrointestinal upset, weight gain, and hypoglycemia."	( The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Harris, KB; Riser Taylor, S, 2013)	0.39
" The pharmacodynamic response to canagliflozin declines with increasing severity of renal impairment, and prescribing information should be consulted regarding dosage adjustments or restrictions in moderate to severe renal dysfunction."	( Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Plosker, GL, 2014)	2.13
" Dosing considerations are required for the elderly, renally impaired, and patients at risk for hypotension."	( Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus. Davis, CS; Fleming, JW; Warrington, LE, 2014)	0.4
"Canagliflozin increased UGE dose-dependently (∼80-120 g/day with canagliflozin ≥100 mg), with increases maintained over the 14-day dosing period with each dose."	( Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. Arnolds, S; Demarest, K; Devineni, D; Ghosh, A; Hompesch, M; Morrow, L; Polidori, D; Rothenberg, P; Sha, S; Spitzer, H, 2014)	2.14
"Canagliflozin increased UGE dose-dependently (,80-120 g/day with canagliflozin $100 mg), with increases maintained over the 14-day dosing period with each dose."	( Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. Arnolds, S; Demarest, K; Devineni, D; Ghosh, A; Hompesch, M; Morrow, L; Polidori, D; Rothenberg, P; Sha, S; Spitzer, H, 2014)	2.14
" The focus of this article is to highlight the FDA's quantitative clinical pharmacology analyses that were conducted to support the regulatory decision on dosing in patients with renal impairment (RI)."	( Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization. Jain, L; Khurana, M; Marathe, A; Mehrotra, N; Sahajwalla, CG; Vaidyanathan, J; Zineh, I, 2015)	1.86
" Compared with sitagliptin 100 mg, canagliflozin 300 mg demonstrated superior diabetes-related quality measure attainment, including glycemic, BP, and weight-related quality measures; there was no difference in LDL-C quality measure attainment between either dosage of canagliflozin and the 100-mg dosage of sitagliptin."	( Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Bailey, RA; Blonde, L; Meininger, GE; Rupnow, MF; Vijapurkar, U, 2014)	0.94
" Thus, prescribing information should be consulted regarding dosage adjustments or restrictions in the case of renal dysfunction for each SGLT2 inhibitor."	( Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Scheen, AJ, 2015)	0.42
"5% to 1% and fasting plasma glucose by ~15 to 35 mg/dL, depending on the agent and the dosage used, and are also associated with modest reductions in weight (-1."	( The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes. Miller, S; Onge, ES; Whalen, K, 2015)	0.42
") dosing with canagliflozin at the same total daily doses of 100 and 300 mg in healthy participants."	( Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Curtin, CR; Devineni, D; Murphy, J; Polidori, D; Stieltjes, H; Wajs, E; Wang, SS, 2015)	1
" dosing or vice versa."	( Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Curtin, CR; Devineni, D; Murphy, J; Polidori, D; Stieltjes, H; Wajs, E; Wang, SS, 2015)	0.64
" The 300-mg dose provides near-maximal effects on RTG throughout the full 24-h dosing interval, whereas the effect of the 100-mg dose on RTG is near-maximal for approximately 12 h and is modestly attenuated during the overnight period."	( Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Devineni, D; Polidori, D, 2015)	0.64
" However, dosage adjustments are recommended for T2DM patients with renal impairment (eGFR ≥60 mL/min/1."	( Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. De Winter, W; Devineni, D; Dunne, A; Hoeben, E; Neyens, M; Vermeulen, A, 2016)	0.7
" The increased risk of UTIs and genital infections seemed to have a dose-response relationship for dapagliflozin only."	( Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Dong, Y; Fang, Z; Li, D; Shen, S; Tang, H; Wang, T, 2017)	0.46
" Only dapagliflozin had a dose-response relationship with UTIs and genital infections."	( Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Dong, Y; Fang, Z; Li, D; Shen, S; Tang, H; Wang, T, 2017)	0.46
"Data from two clinical studies, one with once-daily, and the other with twice-daily dosing of canagliflozin as add-on to metformin were used (n = 1347)."	( Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin. de Trixhe, XW; de Winter, W; Devineni, D; Dunne, A; Hsu, CH; Pinheiro, J; Polidori, D, 2017)	0.87
"Internal and external model validation demonstrated that the model adequately predicted HbA1c-lowering for canagliflozin once-daily and twice-daily dosing regimens."	( Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin. de Trixhe, XW; de Winter, W; Devineni, D; Dunne, A; Hsu, CH; Pinheiro, J; Polidori, D, 2017)	0.86
" While the highest approved dosage of GLP-1RAs lowered HbA1c better than canagliflozin 300-mg, weight and SBP lowering could be non-inferior or slightly better with the latter drug."	( Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists. Singh, AK; Singh, R, 2017)	1.06
" Additionally, the linearity range, limit of detection and limit of quantification were determined and the selectivity was examined through the analysis of laboratory prepared mixtures and the combined dosage form of the drugs."	( Different mathematical processing of absorption, ratio and derivative spectra for quantification of mixtures containing minor component: An application to the analysis of the recently co-formulated antidiabetic drugs; canagliflozin and metformin. Elshahed, MS; Lotfy, HM; Mohamed, D, 2018)	0.67
" In this chronic study male Sprague-Dawley rats were dosed orally with canagliflozin at high dose-levels (65 or 100 mg/kg/day) for 15 months and received either a standard diet or a glucose-free diet."	( Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study. De Jonghe, S; Feyen, B; Johnson, MD; Lammens, G; Mamidi, RNVS; Proctor, J; Vinken, P, 2017)	0.92
" In this study, sensitive and precise spectrophotometric methods were developed for the determination of such hypoglycemic drug combinations in bulk powder and in pharmaceutical dosage form without prior separation."	( Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form. Fawzy, MG; Mahrouse, MA; Moussa, BA, 2018)	0.48
"SGLT2 inhibitors canagliflozin and dapagliflozin resulted in a weight and A1c-independent reduction of ALT levels compared to incretin agents, with a dose-response observed at higher baseline ALT levels."	( SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. Aronson, R; Bajaj, HS; Bhullar, L; Brown, RE; Kalra, S; Sohi, N, 2018)	0.82
" Continued research specific to canagliflozin is needed to clarify risks of adverse effects and determine optimal dosing requirements for canagliflozin in regard to cardiovascular risk reduction."	( Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes. Carter, BS; Roberts, MZ; Skelley, JW, 2018)	1.08
"In this work, the transfer of oral solid dosage forms, currently manufactured via wet granulation, to a continuous direct compression process was considered."	( Systematic development of a high dosage formulation to enable direct compression of a poorly flowing API: A case study. Belen-Girona, J; Castro-Dominguez, B; Croker, DM; Cronin, P; Moroney, KM; Ruane, P; Schaller, BE; Walker, GM, 2019)	0.51
" The PK and PD measurements obtained for rongliflozin demonstrate a dose-response relationship when the drug is administered at doses ranging from 10 to 50 mg in healthy people and in people with T2DM."	( Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus. Chen, H; Ding, Y; Li, C; Li, X; Liu, C; Liu, J; Wu, M; Zhang, H; Zhang, Y; Zhu, X, 2020)	0.56
" Variations in filtered glucose across clinical studies were shown to drive the apparent differences in the glucosuria dose-response relationships among the gliflozins."	( Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. Boulton, DW; Chu, L; Greasley, PJ; Helmlinger, G; Johansson, S; Penland, RC; Peskov, K; Sokolov, V; Tang, W; Yakovleva, T, 2020)	0.79
" Therefore, a meta-analysis was conducted to investigate the weight reduction effects and dose-response relationship of SGLT inhibitors and to assess the relative efficacy of SGLT1/SGLT2 inhibitors."	( SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials. Chai, P; Chan, MY; Cheong, AJY; Chia, AZQ; Chong, EY; Kong, WKF; Lee, CH; Lim, AYL; Ong, HT; Sia, CH; Syn, NL; Teo, YH; Teo, YN; Ting, AZH; Wong, RCC, 2022)	0.72
"The lowest dosage of empagliflozin (10 mg) showed similar benefits on glycated hemoglobin (HbA1c) level, body weight, blood pressure, and total and cardiovascular mortality in comparison with the highest available dose (25 mg) in the EMPAREG trial."	( Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. Gross, JL; Leitão, CB; Pinto, LC; Rados, DV; Remonti, LR; Viana, MV, 2022)	0.72
" Chronic adenine dosing resulted in severe CKD in vehicle-treated rats as indicated by a marked rise in serum creatinine levels, a marked decrease in creatinine clearance, and a disturbed mineral metabolism."	( Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats. Corremans, R; D'Haese, PC; De Broe, ME; Leysen, H; Maudsley, S; Neven, E; Verhulst, A; Vervaet, BA, 2022)	0.72
"0), and the surface under the cumulative ranking curve (SUCRA) score was allotted to each dosage of different SGLT-2i."	( Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis. Bhattacharjee, S; Gamad, N; Hegde, NC; Kasudhan, KS; Kumar, A; Kumar, V; Patil, AN; Rastogi, A, 2023)	0.91
"There is a pressing need for the development of greener liquid chromatographic bioanalytical methods for antidiabetic drugs for plasma monitoring and revisiting patients' dosage regimens."	( Liquid chromatographic methods for the analysis of canagliflozin: concise overview and greener assessment. Haneef, J; Khan, MD, 2023)	1.16

Role	Description
hypoglycemic agent	A drug which lowers the blood glucose level.
sodium-glucose transport protein subtype 2 inhibitor	Any inhibitor that interferes with the action of sodium-glucose transport protein subtype 2.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
C-glycosyl compound	A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a carbon atom, thus creating a C-C bond.
thiophenes	Compounds containing at least one thiophene ring.
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium/glucose cotransporter 1	Homo sapiens (human)	IC50 (µMol)	0.9497	0.0607	1.6105	8.4440	AID1447832; AID1546222; AID670284
Sodium/glucose cotransporter 2	Homo sapiens (human)	IC50 (µMol)	0.0039	0.0005	0.1653	4.1000	AID1396969; AID1447831; AID1546223; AID670283
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium/glucose cotransporter 1	Homo sapiens (human)	EC50 (µMol)	0.9100	0.0011	1.2544	8.3000	AID1546902
Sodium/glucose cotransporter 2	Homo sapiens (human)	EC50 (µMol)	0.0022	0.0011	0.1107	1.3900	AID1546903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
chloride transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
glucose transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
alpha-glucoside transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
intestinal D-glucose absorption	Sodium/glucose cotransporter 1	Homo sapiens (human)
response to inorganic substance	Sodium/glucose cotransporter 1	Homo sapiens (human)
pentose transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
fucose transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
galactose transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
myo-inositol transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
transepithelial water transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
renal glucose absorption	Sodium/glucose cotransporter 1	Homo sapiens (human)
glucose import across plasma membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
sodium ion import across plasma membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
intestinal hexose absorption	Sodium/glucose cotransporter 1	Homo sapiens (human)
transport across blood-brain barrier	Sodium/glucose cotransporter 1	Homo sapiens (human)
glucose transmembrane transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
sodium ion transport	Sodium/glucose cotransporter 1	Homo sapiens (human)
alpha-glucoside transport	Sodium/glucose cotransporter 2	Homo sapiens (human)
carbohydrate metabolic process	Sodium/glucose cotransporter 2	Homo sapiens (human)
hexose transmembrane transport	Sodium/glucose cotransporter 2	Homo sapiens (human)
renal glucose absorption	Sodium/glucose cotransporter 2	Homo sapiens (human)
glucose import across plasma membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
sodium ion import across plasma membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
sodium ion transport	Sodium/glucose cotransporter 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
galactose transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
glucose transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
myo-inositol:sodium symporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
water transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
glucose:sodium symporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
protein binding	Sodium/glucose cotransporter 1	Homo sapiens (human)
pentose transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
fucose transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
alpha-glucoside transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
galactose:sodium symporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
D-glucose transmembrane transporter activity	Sodium/glucose cotransporter 1	Homo sapiens (human)
low-affinity glucose:sodium symporter activity	Sodium/glucose cotransporter 2	Homo sapiens (human)
glucose:sodium symporter activity	Sodium/glucose cotransporter 2	Homo sapiens (human)
protein binding	Sodium/glucose cotransporter 2	Homo sapiens (human)
alpha-glucoside transmembrane transporter activity	Sodium/glucose cotransporter 2	Homo sapiens (human)
D-glucose transmembrane transporter activity	Sodium/glucose cotransporter 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
early endosome	Sodium/glucose cotransporter 1	Homo sapiens (human)
plasma membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
apical plasma membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
brush border membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
intracellular organelle	Sodium/glucose cotransporter 1	Homo sapiens (human)
perinuclear region of cytoplasm	Sodium/glucose cotransporter 1	Homo sapiens (human)
extracellular exosome	Sodium/glucose cotransporter 1	Homo sapiens (human)
intracellular vesicle	Sodium/glucose cotransporter 1	Homo sapiens (human)
plasma membrane	Sodium/glucose cotransporter 1	Homo sapiens (human)
plasma membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
apical plasma membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
extracellular exosome	Sodium/glucose cotransporter 2	Homo sapiens (human)
plasma membrane	Sodium/glucose cotransporter 2	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1447833	Selectivity ratio of IC50 for human SGLT1 expressed in CHO cells to IC50 for human SGLT2 expressed in CHO cells	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
AID670287	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
AID670288	Potency index, ratio of IC50 for CYP3A4 (unknown origin) using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate to IC50 for CYP3A4 using BFC substrate in which compound added to reaction mixture before addition o	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
AID1546903	Inhibition of SGLT2 (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID1447847	Antidiabetic activity in rhesus monkey assessed as increase in urinary glucose excrection at 25 mg/kg, po administered as single dose 30 mins prior to glucose challenge and subsequent re-feeding after 1 hr of glucose challenge measured less than 3 days	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
AID670285	Selectivity index, ratio of IC50 for human SGLT1 to IC50 for human SGLT2	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
AID1447841	Antidiabetic activity in Sprague-Dawley rat assessed as increase in urinary glucose excrection at 1 to 10 mg/kg, po administered as single dose 30 mins prior to glucose challenge and subsequent re-feeding after 1 hr of glucose challenge measured after 24	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
AID1546902	Inhibition of SGLT1 (unknown origin)	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
AID670283	Inhibition of human SGLT2 expressed in CHO-K1 cells by [14C]AMG uptake assay	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
AID1546222	Inhibition of human SGLT1	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
AID1546223	Inhibition of human SGLT2	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
AID1447831	Inhibition of human SGLT2 expressed in CHO cells assessed as decrease in uptake of [14C]AMG after 120 mins by TopCount method	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
AID1396969	Inhibition of SGLT2 (unknown origin)	2018	Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14	Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents.
AID670286	Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
AID1447832	Inhibition of human SGLT1 expressed in CHO cells assessed as decrease in uptake of [14C]AMG after 120 mins by TopCount method	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
AID670284	Inhibition of human SGLT1 expressed in CHO-K1 cells by [14C]AMG uptake assay	2012	Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13	C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
AID1546232	Selectivity ratio of IC50 for inhibition of human SGLT1 to IC50 for inhibition of human SGLT2	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346965	Human Sodium/glucose cotransporter 2 (Hexose transporter family)	2012	PloS one, , Volume: 7, Issue:2	Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
AID1346950	Human Sodium/glucose cotransporter 1 (Hexose transporter family)	2012	PloS one, , Volume: 7, Issue:2	Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	588 (60.25)	24.3611
2020's	388 (39.75)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	194 (19.44%)	5.53%
Reviews	220 (22.04%)	6.00%
Case Studies	45 (4.51%)	4.05%
Observational	30 (3.01%)	0.25%
Other	509 (51.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (133)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open-Label, Single-Dose Study to Assess the Absolute Oral Bioavailability and Pharmacokinetics of JNJ-28431754 (Canagliflozin) Administered as a 300-mg Oral Tablet and an Intravenous Microdose of 10 mcg 14C-canagliflozin in Healthy Male Subjects [NCT01157000]	Phase 1	9 participants (Actual)	Interventional	2010-05-31	Completed
An Open-Label, Randomized, Parallel-Group, Single-Center Study to Evaluate the Single and Multiple Dose Pharmacokinetic and Pharmacodynamic Characteristics of JNJ-28431754 (Canagliflozin) in Healthy Subjects [NCT01281579]	Phase 1	27 participants (Actual)	Interventional	2011-01-31	Completed
A Double-Blind, Randomized, Placebo Controlled, 2-Period Crossover Study to Evaluate the Effect of a Single Dose of JNJ-28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Subjects [NCT01173549]	Phase 1	26 participants (Actual)	Interventional	2010-11-30	Completed
An Open-Label, Multiple-Dose Study to Assess the Steady-State Pharmacokinetics, Pharmacodynamics and Safety of Once-Daily Versus Twice-Daily Dosing With Canagliflozin in Healthy Subjects [NCT01286103]	Phase 1	34 participants (Actual)	Interventional	2011-01-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Single-Center, Mechanistic Study to Evaluate the Effects of Canagliflozin on Intravascular Volume and Hemodynamics in Subjects With Type 2 Diabetes Mellitus and Heart Failure [NCT03190798]	Phase 4	0 participants (Actual)	Interventional	2017-09-01	Withdrawn(stopped due to Study has been withdrawn from IRB review pending IND revision)
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who H [NCT01064414]	Phase 3	272 participants (Actual)	Interventional	2010-06-30	Completed
A Double-Blind, Placebo-Controlled, Randomized, Crossover, Multicenter Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Subjects With Type 2 Diabetes Mellitus [NCT01381887]	Phase 1	37 participants (Actual)	Interventional	2011-06-30	Completed
An Open-Label, Single-Dose, Randomized, 3-Period, Crossover Study to Evaluate the Pharmacokinetic Dose Proportionality of Canagliflozin of 50, 100, and 300 mg Under Fasted Conditions in Healthy Subjects [NCT01340677]	Phase 1	24 participants (Actual)	Interventional	2011-05-31	Completed
Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES) [NCT03627039]		20,000 participants (Anticipated)	Observational	2018-09-01	Active, not recruiting
Retrospective Observational Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Patients With BMI>25 kg/m^2, in Real World Clinical Setting [NCT03604224]		178 participants (Actual)	Observational	2018-09-05	Completed
An Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of 300 mg JNJ-28431754 (Canagliflozin) in Subjects With Various Degrees of Impaired Hepatic Function Compared With Subjects With Normal Hepatic Function [NCT01186588]	Phase 1	24 participants (Actual)	Interventional	2010-08-31	Completed
An Open-Label Drug Interaction Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Administered Alone and in Combination With Multiple-Dose JNJ-28431754 (Canagliflozin) in Healthy Male and Female Subjects [NCT01195324]	Phase 1	14 participants (Actual)	Interventional	2010-09-30	Completed
Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus [NCT03249506]		25,358 participants (Actual)	Observational	2016-05-12	Completed
Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes [NCT02912455]	Phase 4	16 participants (Actual)	Interventional	2017-01-05	Terminated(stopped due to Study was terminated due to difficulty with reaching enrollment goals)
A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 50 mg/500 mg) With Respect to the Individual Components of Ca [NCT02065752]	Phase 1	2 participants (Actual)	Interventional	2014-02-28	Completed
A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 150 mg/500 mg) With Respect to the Individual Components of C [NCT02071368]	Phase 1	3 participants (Actual)	Interventional	2014-02-28	Completed
A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release (IR) 1 x (50 mg/500 mg) With Respect to the [NCT02220218]	Phase 1	2 participants (Actual)	Interventional	2014-08-31	Completed
A Single-Dose, Open-Label, Randomized, 2-Period, 2-Sequence, Crossover Study to Determine the Effect of Food Coadministration on the Pharmacokinetics of 300 mg Canagliflozin in Healthy Subjects [NCT01343290]	Phase 1	24 participants (Actual)	Interventional	2011-04-30	Completed
Intraclass Safety and Efficacy Comparison Among SGLT-2 Inhibitors in Elderly Patients With Type 2 Diabetes. A Pragmatic, Phase IV, Multicenter, Open-label, Randomised Controlled Trial. [NCT04796428]	Phase 4	1,167 participants (Anticipated)	Interventional	2021-06-30	Not yet recruiting
A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 50 mg/1,000 mg) With Respect to the Individual Components of [NCT02077803]	Phase 1	47 participants (Actual)	Interventional	2014-03-31	Completed
Impact of Canaglifloxin on Gut Hormone Secretion After Gastric Bypass [NCT03426956]		10 participants (Anticipated)	Interventional	2018-02-08	Recruiting
Effect of Glimepiride, Vildagliptin, Pioglitazone and Canagliflozin on Durability of Glycemic Control After Metformin Failure in Type 2 Diabetes [NCT02142309]	Phase 4	450 participants (Anticipated)	Interventional	2005-10-31	Recruiting
Assessment of the Renin-angiotensin-aldosterone System (RAAS) and Antidiuretic Function in Patients With Type 2 Diabetes Before and During Treatment With Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i): the GliRACo 1 Study [NCT03917758]		30 participants (Anticipated)	Interventional	2018-10-10	Recruiting
A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release (IR) 1 x (150 mg/500 mg) With Respect to the [NCT02221180]	Phase 1	2 participants (Actual)	Interventional	2014-08-31	Completed
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes [NCT03136484]	Phase 3	788 participants (Actual)	Interventional	2017-03-15	Completed
A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Multiple Dose Pharmacokinetic and Pharmacodynamic Characteristics of JNJ-28431754 (Canagliflozin) in Subjects With Type 2 Diabetes Mellitus [NCT01128985]	Phase 1	39 participants (Actual)	Interventional	2010-03-31	Completed
Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease [NCT03492580]		714,582 participants (Actual)	Observational	2018-02-22	Completed
Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure [NCT04252287]	Phase 3	476 participants (Actual)	Interventional	2020-03-10	Completed
Canagliflozin Continuous Glucose Monitoring (CANA CGM) Trial: A Pilot Randomized, Double-Blind, Controlled, Crossover Study on the Effects of the SGLT-2 Inhibitor Canagliflozin (vs. the DPP-4 Inhibitor Sitagliptin) on Glucose Variability in Mexican Patien [NCT03267576]	Phase 4	64 participants (Actual)	Interventional	2017-10-27	Completed
An Open-Label, Two-Period, Fixed-Sequence Study to Explore the Effects of Multiple Doses of Hydrochlorothiazide on the Pharmacodynamics, Pharmacokinetics, and Safety of Multiple Doses of Canagliflozin in Healthy Subjects [NCT01294631]	Phase 1	30 participants (Actual)	Interventional	2011-03-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin as Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Di [NCT01081834]	Phase 3	678 participants (Actual)	Interventional	2010-03-31	Completed
Pharmacogenomics to Predict Responses to SGLT2 Inhibitors [NCT02891954]	Phase 1	700 participants (Anticipated)	Interventional	2016-09-30	Enrolling by invitation
A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (50 mg/500 mg) With Respect to the M [NCT02865668]	Phase 1	44 participants (Actual)	Interventional	2016-08-31	Completed
TriMaster: Randomised Double-Blind Crossover Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes Who Have Suboptimal Glycaemic Control on Dual Therapy With Metformin and a Sulphonylurea [NCT02653209]	Phase 4	525 participants (Actual)	Interventional	2016-11-01	Completed
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus [NCT01032629]	Phase 3	4,330 participants (Actual)	Interventional	2009-12-09	Completed
Nanjing Medical University, Nanjing First Hospital [NCT05856578]	Phase 4	60 participants (Actual)	Interventional	2022-03-15	Active, not recruiting
A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 150 mg/1,000 mg) With Respect to the Individual Components of [NCT02073227]	Phase 1	52 participants (Actual)	Interventional	2014-02-28	Completed
Harmonizing RCT-Duplicate Emulations: A Real World Replication Program Analyzing Three Clinical Trials, CANVAS, LEADER, and SAVOR TIMI in Type 2 Diabetes Mellitus [NCT06099067]		239,990 participants (Actual)	Observational	2020-05-15	Completed
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of JNJ-28431754 in Type 2 Diabetes Mellitus Patients [NCT00963768]	Phase 1	116 participants (Actual)	Interventional	2007-06-30	Completed
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients [NCT02324842]		45 participants (Actual)	Interventional	2014-11-30	Completed
Clinical Efficacy of SGLT-2 Inhibitor After Stent Implantation in Patients With Coronary Heart Disease and Diabetes Mellitus：a Prospective Cohort Study [NCT05333159]		1,424 participants (Anticipated)	Observational	2021-09-01	Recruiting
Canagliflozin Administration in Non-diabetic Women With Polycystic Ovarian Syndrome [NCT04973891]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2021-04-07	Completed
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors With PIK3CA or KRAS Mutations [NCT04073680]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2020-09-01	Not yet recruiting
Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study [NCT04127084]	Phase 4	70 participants (Anticipated)	Interventional	2019-10-15	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects [NCT00650806]	Phase 2	376 participants (Actual)	Interventional	2008-05-31	Completed
Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes [NCT02964585]	Phase 4	34 participants (Actual)	Interventional	2016-11-30	Completed
A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (50 mg/1000 mg) With Respect to the [NCT02851095]	Phase 1	44 participants (Actual)	Interventional	2016-08-31	Completed
Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment [NCT02041234]	Phase 4	40 participants (Anticipated)	Interventional	2014-02-28	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Contr [NCT01106651]	Phase 3	716 participants (Actual)	Interventional	2010-06-30	Completed
Safety and Efficacy of Canagliflozin in Advanced CKD [NCT05309785]	Phase 4	44 participants (Anticipated)	Interventional	2022-11-24	Recruiting
An Open-Label, Fixed-Sequence Study to Assess Effects of Steady-State Rifampin on the Single-Dose Pharmacokinetics of Canagliflozin in Healthy Subjects [NCT01395927]	Phase 1	14 participants (Actual)	Interventional	2011-07-31	Completed
Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV: A Randomized Controlled Trial. [NCT05135039]		218 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Molecular Mechanisms of SGLT2 Inhibition in Diabetic Kidney Disease [NCT05507892]	Phase 2	40 participants (Anticipated)	Interventional	2022-10-10	Recruiting
Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus [NCT04014192]	Phase 4	40 participants (Anticipated)	Interventional	2019-09-01	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Met [NCT01106690]	Phase 3	344 participants (Actual)	Interventional	2010-06-30	Completed
A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (150 mg/1000 mg) With Respect to the [NCT02851212]	Phase 1	44 participants (Actual)	Interventional	2016-08-31	Completed
The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With ≥200 Units Per Day of U-500 Insulin [NCT02597309]	Phase 4	0 participants (Actual)	Interventional	2015-11-30	Withdrawn
A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 [NCT00642278]	Phase 2	451 participants (Actual)	Interventional	2008-04-30	Completed
A Double-Blind, Randomized, 2-Way Crossover Study to Compare the Pharmacodynamics of Canagliflozin 300 mg Versus Dapagliflozin 10 mg in Healthy Subjects [NCT01877889]	Phase 1	60 participants (Actual)	Interventional	2013-07-31	Completed
A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA™ (Canagliflozin) in Healthy Subjects Using Stable Isotope Tracer Methods [NCT01916863]	Phase 1	25 participants (Actual)	Interventional	2013-08-31	Completed
Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metf [NCT02000700]	Phase 1	17 participants (Actual)	Interventional	2014-03-31	Completed
A Double-Blind, Placebo-Controlled, Randomized, Parallel Groups, Multicenter Study to Investigate the Effects of Canagliflozin on Insulin Sensitivity, Hepatic Fat Content and Beta Cell Function in Subjects With Type 2 Diabetes Mellitus [NCT02009488]	Phase 1	59 participants (Actual)	Interventional	2014-09-08	Completed
Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A Phase 2 Randomized Control Trial in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer [NCT05090358]	Phase 2	106 participants (Anticipated)	Interventional	2021-10-08	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Met [NCT01340664]	Phase 2	279 participants (Actual)	Interventional	2011-07-31	Completed
A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Con [NCT01106677]	Phase 3	1,284 participants (Actual)	Interventional	2010-05-31	Completed
A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study [NCT02694263]	Phase 4	25 participants (Actual)	Interventional	2016-07-31	Completed
A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (150 mg/500 mg) With Respect to the [NCT02846506]	Phase 1	44 participants (Actual)	Interventional	2016-08-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Met [NCT01106625]	Phase 3	469 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Co [NCT00968812]	Phase 3	1,452 participants (Actual)	Interventional	2009-09-30	Completed
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformi [NCT01137812]	Phase 3	756 participants (Actual)	Interventional	2010-07-31	Completed
An Open-Label, Fixed-Sequence Study to Assess the Effects of Multiple-Dose Probenecid on the Multiple-Dose Pharmacokinetics of Canagliflozin in Healthy Subjects [NCT01428284]	Phase 1	14 participants (Actual)	Interventional	2011-08-31	Completed
A Double-Blind, Placebo-Controlled, Randomized, Parallel-Groups Study to Investigate the Effects of JNJ-28431754 (Canagliflozin) on Plasma Volume and Renal Function in Subjects With Type 2 Diabetes Mellitus [NCT01483781]	Phase 1	36 participants (Actual)	Interventional	2011-12-31	Completed
A Prospective, Multi-centric, Open-label, Single-arm, Phase 4 Study to Evaluate the Safety and Efficacy of Canagliflozin + Metformin Hydrochloride IR Fixed-dose Combination as an Adjunct to Diet and Exercise to Improve Glycemic Control in Indian Adult Pat [NCT04288778]	Phase 4	276 participants (Actual)	Interventional	2020-11-25	Completed
An Open-label Drug-Drug Interaction Study in Healthy Female Subjects to Explore the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics and Safety of Single Doses of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel [NCT01714193]	Phase 1	30 participants (Actual)	Interventional	2008-02-29	Completed
Canagliflozin in Advanced Renal Disease With MRI Endpoints [NCT06182839]	Phase 2	92 participants (Anticipated)	Interventional	2024-03-30	Not yet recruiting
Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers [NCT02404870]	Phase 1	67 participants (Actual)	Interventional	2014-09-16	Completed
Mechanism of the Effect by Sodium-glucose Cotransporter-2 Inhibitor on Obesity Associated Cardiomyopathy [NCT05764811]		40 participants (Actual)	Interventional	2020-03-06	Completed
A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagl [NCT01518712]	Phase 1	64 participants (Actual)	Interventional	2011-09-30	Completed
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study [NCT05220917]		781,430 participants (Anticipated)	Observational	2021-08-01	Active, not recruiting
An Open-Label, Fixed Sequence Study to Investigate the Potential for Pharmacokinetic and Pharmacodynamic Interaction Between Single-Dose Metformin and Multiple-Dose Canagliflozin in Healthy Subjects [NCT01273571]	Phase 1	18 participants (Actual)	Interventional	2010-12-31	Completed
Effect of Canagliflozin in T1DM After Interruption of Continuous Subcutaneous Insulin Infusion [NCT02673138]		10 participants (Actual)	Interventional	2016-01-31	Completed
Canagliflozin Targeting Vascular Inflammation: An Ottawa Imaging Study - A Pilot Study [NCT05427084]	Phase 2/Phase 3	24 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Canagliflozin: a New Therapeutic Option in Patients That Present Postprandial Hyperinsulinemic Hypoglycemia After Roux-en-Y-gastric By-pass [NCT04720859]		40 participants (Anticipated)	Interventional	2018-01-05	Recruiting
Therapeutic Effects of Canagliflozin on the Liver Inflammation Damage and Lipoprotein Metabolism in Patients With Type 2 Diabetes Mellitus Combined With Nonalcoholic Fatty Liver Disease [NCT05422092]		80 participants (Anticipated)	Interventional	2022-09-20	Not yet recruiting
A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 FDC Tablets of Canagliflozin and Metformin IR (150 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1x300 mg) and Metformin IR Tab [NCT01508182]	Phase 1	64 participants (Actual)	Interventional	2012-01-31	Completed
A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 FDC Tablets of Canagliflozin and Metformin IR (50 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Ta [NCT01508195]	Phase 1	64 participants (Actual)	Interventional	2012-01-31	Completed
A Double-Blind, Randomized, Placebo-Controlled, 2-Way Cross-Over Study to Evaluate the Effect of Single Dose Canagliflozin on Kinetics of C-Peptide in Healthy Subjects [NCT01665638]	Phase 1	10 participants (Actual)	Interventional	2012-09-30	Completed
A Double-Blind, Randomized, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of JNJ-28431754 (Canagliflozin) in Healthy Chinese Subjects [NCT01707316]	Phase 1	15 participants (Actual)	Interventional	2012-06-30	Completed
An Open-Label, 2-Period, Crossover Study to Evaluate the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics of Multiple Doses of Digoxin in Healthy Subjects. [NCT01714206]	Phase 1	18 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypert [NCT01939496]	Phase 4	171 participants (Actual)	Interventional	2013-10-31	Completed
An Open-Label, Single Sequence Study to Assess the Effect of a Single Dose of Cyclosporine on the Steady-State Pharmacokinetics of JNJ-28431754 (Canagliflozin) in Healthy Adult Subjects [NCT01718652]	Phase 1	18 participants (Actual)	Interventional	2011-02-28	Completed
An Open-Label Drug-Drug Interaction Study in Healthy Subjects to Explore the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics and Safety of Single Doses of Glyburide [NCT01733108]	Phase 1	29 participants (Actual)	Interventional	2008-07-31	Completed
A Single-Dose, Open-Label, Randomized, Two-Way, Cross-Over Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-28431754 in Healthy Indian Subjects [NCT01748526]	Phase 1	16 participants (Actual)	Interventional	2008-08-31	Completed
A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of JNJ-28431754 in Otherwise Healthy Obese Male and Female Subjects [NCT01756404]	Phase 1	80 participants (Actual)	Interventional	2007-06-14	Completed
An Open-Label, Fixed Sequence, Single and Multiple Dose Study in Male and Female Subjects to Investigate the Potential for Pharmacokinetic and Pharmacodynamic Interaction Between Metformin and JNJ-28431754 [NCT01756417]	Phase 1	18 participants (Actual)	Interventional	2007-10-31	Completed
An Open-Label, Single-Dose Study to Evaluate JNJ-28431754 Pharmacokinetics, Pharmacodynamics and Safety in Non-Diabetic Subjects With Varying Degrees of Renal Function [NCT01759576]	Phase 1	40 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Four-Way Crossover Study Evaluating ECG Intervals in Healthy Adults Receiving a Single, Oral Dose of JNJ-28431754 at Therapeutic and Supra-Therapeutic Doses [NCT01787357]	Phase 1	60 participants (Actual)	Interventional	2008-06-30	Completed
A Open-Label, Single Sequence Study to Assess the Pharmacokinetics and Pharmacodynamics of Simvastatin Alone and of Simvastatin in Combination With JNJ-28431754 in Healthy Adult Subjects [NCT01821027]	Phase 1	22 participants (Actual)	Interventional	2008-08-31	Completed
Pharmacogenetics of Sodium-dependent Glucose Transporter-2 (SGLT2) Inhibitors [NCT02462421]	Phase 4	30 participants (Actual)	Interventional	2015-06-01	Terminated(stopped due to Did not meet recruitment targets.)
Replication of Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS Trial) [NCT03936010]		152,202 participants (Actual)	Observational	2017-09-22	Completed
A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of FDC Tablets of Canagliflozin and Metformin IR (2x150 mg/1000 mg) With Respect to the Individual Components of Canagliflozin (1x300 mg) and Metformin IR (2 [NCT01463228]	Phase 1	83 participants (Actual)	Interventional	2011-09-30	Completed
Pivotal BE CANA/MET IR FDC - Low Strength [NCT01463774]	Phase 1	74 participants (Actual)	Interventional	2011-09-30	Completed
Canagliflozin-Mealtime Insulin Rescue [NCT02624908]	Phase 4	40 participants (Anticipated)	Interventional	2016-01-31	Active, not recruiting
Clinical Study of Capeline Combined With Gemcitabine in the Treatment of Pancreatic Cancer [NCT05903703]		20 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy [NCT03436693]	Phase 3	308 participants (Actual)	Interventional	2018-02-15	Completed
Therapeutic Effects of Canagliflozin on the Liver Inflammation Damage and Lipoprotein Metabolism in Patients With Type 2 Diabetes Mellitus Combined With Nonalcoholic Fatty Liver Disease [NCT05513729]		80 participants (Anticipated)	Observational [Patient Registry]	2022-08-18	Recruiting
Investigating the Protective Effect of Newer Antidiabetic Drugs on Cognitive Decline in Diabetic Patients [NCT05347459]		100 participants (Anticipated)	Observational	2022-03-02	Recruiting
A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure [NCT02920918]	Phase 4	36 participants (Actual)	Interventional	2016-10-31	Completed
Mechanisms of Weight Loss With SGLT2 Inhibition [NCT02360774]	Phase 4	30 participants (Actual)	Interventional	2015-02-28	Completed
A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 FDC Tablets of Canagliflozin and Metformin IR (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR [NCT01454622]	Phase 1	64 participants (Actual)	Interventional	2011-09-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of the Co-administration of Canagliflozin 300 mg and Phentermine 15 mg Compared With Placebo for the Treatment of Non-diabetic Overweight and Obese [NCT02243202]	Phase 2	335 participants (Actual)	Interventional	2014-09-30	Completed
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin in Patients With Inadequate Glycemic Control on Teneligliptin) [NCT02354235]	Phase 3	138 participants (Actual)	Interventional	2015-01-31	Completed
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy [NCT02065791]	Phase 3	4,401 participants (Actual)	Interventional	2014-02-17	Completed
An Open-Label Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-28431754 in Healthy Male Subjects Following a Single Oral Dose Administration of 14C-JNJ-28431754 [NCT01791231]	Phase 1	6 participants (Actual)	Interventional	2007-08-31	Completed
A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus [NCT02597049]	Phase 3	424 participants (Actual)	Interventional	2015-11-30	Completed
A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus [NCT01989754]	Phase 4	5,813 participants (Actual)	Interventional	2014-01-16	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 18-Week Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alon [NCT01381900]	Phase 3	678 participants (Actual)	Interventional	2011-08-31	Completed
An Open-Label Study to Compare Two Methods for Determining the Renal Threshold for Glucose in Subjects With Type 2 Diabetes Mellitus [NCT01273558]	Phase 1	28 participants (Actual)	Interventional	2011-01-31	Completed
A Randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Contr [NCT02025907]	Phase 4	218 participants (Actual)	Interventional	2014-02-28	Completed
An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus [NCT02622113]	Phase 4	139 participants (Actual)	Interventional	2014-12-31	Completed
Effect of Canagliflozin on Cardiac Microcirculation Function in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Risk Factors [NCT05367063]	Phase 4	70 participants (Anticipated)	Interventional	2022-01-05	Recruiting
Efficacy and Safety of Early Initiation of Canagliflozin in Patients With Acute Decompansted Heart Failure [NCT05364190]	Phase 3	144 participants (Anticipated)	Interventional	2022-06-04	Recruiting
Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. [NCT04662723]	Phase 4	878 participants (Anticipated)	Interventional	2023-05-01	Recruiting
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 Years) With Type 2 Diabetes Mellitus [NCT03170518]	Phase 3	171 participants (Actual)	Interventional	2017-07-21	Completed
A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects With Type 1 Diabetes Mellitus [NCT02139943]	Phase 2	352 participants (Actual)	Interventional	2014-05-31	Completed
The Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome: A Randomized, Open Label Trial [NCT04700839]	Phase 4	68 participants (Actual)	Interventional	2020-05-01	Completed
A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabete [NCT01809327]	Phase 3	1,186 participants (Actual)	Interventional	2013-06-04	Completed
Subclinical Inflammation, Myocardial Function and Fatty Acid Metabolism in Patients With Type 2 Diabetes and Heart Failure: Impact of a Short-term Treatment With Canagliflozin - a Pilot Study [NCT03298009]		0 participants (Actual)	Interventional	2017-11-01	Withdrawn(stopped due to end of contract negociations)
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19 [NCT04505774]	Phase 4	880 participants (Actual)	Interventional	2020-09-04	Active, not recruiting
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin in Patients With Inadequate Glycemic Control on Canagliflozin) [NCT02354222]	Phase 3	154 participants (Actual)	Interventional	2015-01-31	Completed
An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to GLP-1 Analogue in Subjects With Type 2 Diabetes Mellitus [NCT02227849]	Phase 4	71 participants (Actual)	Interventional	2014-08-31	Completed
Long-term Administration Study of MT-2412 in Patients With Type 2 Diabetes Mellitus [NCT02220907]	Phase 3	153 participants (Actual)	Interventional	2014-08-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus [NCT02220920]	Phase 4	146 participants (Actual)	Interventional	2014-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00642278 (6) [back to overview]	Percent Change in Body Weight From Baseline to Week 12
NCT00642278 (6) [back to overview]	Absolute Change in Body Weight From Baseline to Week 12
NCT00642278 (6) [back to overview]	Change in Overnight Urine Glucose/Creatinine Ratio From Baseline to Week 12
NCT00642278 (6) [back to overview]	Change in HbA1c From Baseline to Week 12
NCT00642278 (6) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 12
NCT00642278 (6) [back to overview]	Percentage of Patients With Symptoms of Hypoglycemia
NCT00650806 (8) [back to overview]	Change in Waist Circumference From Baseline to Week 12
NCT00650806 (8) [back to overview]	Change in Hip Circumference From Baseline to Week 12
NCT00650806 (8) [back to overview]	Change in Body Mass Index (BMI) From Baseline to Week 12
NCT00650806 (8) [back to overview]	Absolute Change in Body Weight From Baseline to Week 12
NCT00650806 (8) [back to overview]	Percentage of Patients Who Lost at Least 5% of Their Initial Body Weight by Week 12
NCT00650806 (8) [back to overview]	Percentage of Patients Who Lost at Least 10% of Their Initial Body Weight by Week 12
NCT00650806 (8) [back to overview]	Percent Change in Body Weight From Baseline to Week 12
NCT00650806 (8) [back to overview]	Change in Waist/Hip Ratio From Baseline to Week 12
NCT00968812 (4) [back to overview]	Change in HbA1c From Baseline to Week 104
NCT00968812 (4) [back to overview]	Change in HbA1c From Baseline to Week 52
NCT00968812 (4) [back to overview]	Percent Change in Body Weight From Baseline to Week 52
NCT00968812 (4) [back to overview]	Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52
NCT01032629 (13) [back to overview]	Change From Baseline in Homeostasis Model Assessment 2 Steady-State Beta-Cell Function (HOMA2-%B) at the End-of-Treatment (EOT)
NCT01032629 (13) [back to overview]	Change From Baseline in Glycated Hemoglobin (HbA1c) at End-of-Treatment
NCT01032629 (13) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) Levels at End-of-Treatment
NCT01032629 (13) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at End-of-Treatment
NCT01032629 (13) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End-of-Treatment
NCT01032629 (13) [back to overview]	Change From Baseline in Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) Levels at End-of-Treatment
NCT01032629 (13) [back to overview]	Percentage of Participants With Progression of Albuminuria at the End-of-Treatment
NCT01032629 (13) [back to overview]	Percent Change From Baseline in Body Weight at End-of-Treatment
NCT01032629 (13) [back to overview]	Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke
NCT01032629 (13) [back to overview]	Change From Baseline in Urinary Albumin/Creatinine Ratio at End-of-Treatment
NCT01032629 (13) [back to overview]	Change From Baseline in Triglycerides Levels at End-of-Treatment
NCT01032629 (13) [back to overview]	Change From Baseline in Proinsulin/Insulin (PI/I) Ratio at the End-of-Treatment
NCT01032629 (13) [back to overview]	Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment
NCT01064414 (3) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT01064414 (3) [back to overview]	Percentage of Patients With HbA1c <7% at Week 26
NCT01064414 (3) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
NCT01081834 (16) [back to overview]	Change in HbA1c From Baseline to Week 26 (Main Study)
NCT01081834 (16) [back to overview]	Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (High Glycemic Substudy)
NCT01081834 (16) [back to overview]	Percent Change in Body Weight From Baseline to Week 26 (Main Study)
NCT01081834 (16) [back to overview]	Percent Change in Body Weight From Baseline to Week 26 (High Glycemic Substudy)
NCT01081834 (16) [back to overview]	Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (Main Study)
NCT01081834 (16) [back to overview]	Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (High Glycemic Substudy)
NCT01081834 (16) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy)
NCT01081834 (16) [back to overview]	Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)
NCT01081834 (16) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (Main Study)
NCT01081834 (16) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (High Glycemic Substudy)
NCT01081834 (16) [back to overview]	Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (Main Study)
NCT01081834 (16) [back to overview]	Percentage of Patients With HbA1c <7% at Week 26 (Main Study)
NCT01081834 (16) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (Main Study)
NCT01081834 (16) [back to overview]	Percent Change in Triglycerides From Baseline to Week 26 (High Glycemic Substudy)
NCT01081834 (16) [back to overview]	Percent Change in Triglycerides From Baseline to Week 26 (Main Study)
NCT01081834 (16) [back to overview]	Percentage of Patients With HbA1c <7% at Week 26 (High Glycemic Substudy)
NCT01106625 (7) [back to overview]	Percent Change in Triglycerides From Baseline to Week 26
NCT01106625 (7) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26
NCT01106625 (7) [back to overview]	Percent Change in Body Weight From Baseline to Week 26
NCT01106625 (7) [back to overview]	Change in Systolic Blood Pressure (SBP) From Baseline to Week 26
NCT01106625 (7) [back to overview]	Percentage of Patients With HbA1c <7% at Week 26
NCT01106625 (7) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
NCT01106625 (7) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT01106651 (14) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT01106651 (14) [back to overview]	Percent Change in Body Weight From Baseline to Week 26
NCT01106651 (14) [back to overview]	Percentage of Patients With HbA1c <7% at Week 26
NCT01106651 (14) [back to overview]	Change in Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition
NCT01106651 (14) [back to overview]	Percent Change in Triglycerides From Baseline to Week 26
NCT01106651 (14) [back to overview]	Percent Change in Total Hip Bone Mineral Density (BMD) From Baseline to Week 26
NCT01106651 (14) [back to overview]	Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to Week 26
NCT01106651 (14) [back to overview]	Percent Change in Femoral Neck Bone Mineral Density (BMD) From Baseline to Week 26
NCT01106651 (14) [back to overview]	Percent Change in Distal Forearm Bone Mineral Density (BMD) From Baseline to Week 26
NCT01106651 (14) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
NCT01106651 (14) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26
NCT01106651 (14) [back to overview]	Change in Tissue Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition
NCT01106651 (14) [back to overview]	Change in Systolic Blood Pressure (SBP) From Baseline to Week 26
NCT01106651 (14) [back to overview]	Change in Region Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition
NCT01106677 (14) [back to overview]	Change in 2-hour Post-prandial Glucose From Baseline to Week 26
NCT01106677 (14) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26
NCT01106677 (14) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52
NCT01106677 (14) [back to overview]	Percent Change in Triglycerides From Baseline to Week 26
NCT01106677 (14) [back to overview]	Change in Systolic Blood Pressure (SBP) From Baseline to Week 52
NCT01106677 (14) [back to overview]	Percentage of Patients With HbA1c <7% at Week 26
NCT01106677 (14) [back to overview]	Change in HbA1c From Baseline to Week 52
NCT01106677 (14) [back to overview]	Percent Change in Body Weight From Baseline to Week 26
NCT01106677 (14) [back to overview]	Percent Change in Body Weight From Baseline to Week 52
NCT01106677 (14) [back to overview]	Change in Systolic Blood Pressure (SBP) From Baseline to Week 26
NCT01106677 (14) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT01106677 (14) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52
NCT01106677 (14) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
NCT01106677 (14) [back to overview]	Percent Change in Triglycerides From Baseline to Week 52
NCT01106690 (8) [back to overview]	Change in Homeostasis Model Assessment (HOMA2-%B) From Baseline to Week 26
NCT01106690 (8) [back to overview]	Change in HbA1c From Baseline to Week 26
NCT01106690 (8) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26
NCT01106690 (8) [back to overview]	Change in Systolic Blood Pressure (SBP) From Baseline to Week 26
NCT01106690 (8) [back to overview]	Percentage of Patients With HbA1c <7% at Week 26
NCT01106690 (8) [back to overview]	Percent Change in Triglycerides From Baseline to Week 26
NCT01106690 (8) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26
NCT01106690 (8) [back to overview]	Percent Change in Body Weight From Baseline to Week 26
NCT01137812 (7) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52
NCT01137812 (7) [back to overview]	Percent Change in Body Weight From Baseline to Week 52
NCT01137812 (7) [back to overview]	Change in Systolic Blood Pressure (SBP) From Baseline to Week 52
NCT01137812 (7) [back to overview]	Change in HbA1c From Baseline to Week 52
NCT01137812 (7) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 52
NCT01137812 (7) [back to overview]	Percentage of Patients With HbA1c <7% at Week 52
NCT01137812 (7) [back to overview]	Percent Change in Triglycerides From Baseline to Week 52
NCT01340664 (4) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 18
NCT01340664 (4) [back to overview]	Percentage of Patients With HbA1c <7% at Week 18
NCT01340664 (4) [back to overview]	Change in HbA1c From Baseline to Week 18
NCT01340664 (4) [back to overview]	Percent Change in Body Weight From Baseline to Week 18
NCT01381900 (5) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline to Week 18
NCT01381900 (5) [back to overview]	Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18
NCT01381900 (5) [back to overview]	Percent Change in Body Weight From Baseline to Week 18
NCT01381900 (5) [back to overview]	Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <7% at Week 18
NCT01381900 (5) [back to overview]	Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <6.5% at Week 18
NCT01809327 (7) [back to overview]	Change in Systolic Blood Pressure From Baseline at Week 26
NCT01809327 (7) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (AEs)
NCT01809327 (7) [back to overview]	Percent Change in Body Weight From Baseline to Week 26
NCT01809327 (7) [back to overview]	Percent Change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26
NCT01809327 (7) [back to overview]	Percent Change in Triglycerides From Baseline to Week 26
NCT01809327 (7) [back to overview]	Percentage of Participants With Glycated Hemoglobin (HbAIc) Less Than 7 Percent at Week 26
NCT01809327 (7) [back to overview]	Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26
NCT01939496 (15) [back to overview]	Change From Baseline in Standing Heart Rate (HR) to Day 2, to Week 3, and to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in Standing Office Blood Pressure (BP) to Day 2, to Week 3, and to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in the Difference in Seated Heart Rate (HR) and Standing HR to Day 2, to Week 3, and to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in the Difference in Seated Office Blood Pressure (BP) and Standing Office BP to Day 2, to Week 3, and to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in the Mean 24-Hour Diastolic Blood Pressure (DBP) to Day 2 and to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in the Mean 24-Hour Systolic Blood Pressure (SBP) to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in Mean Nighttime Systolic Blood Pressure (SBP) to Day 2 and to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in Seated Heart Rate (HR) to Day 2, to Week 3, and to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in Seated Office Blood Pressure (BP) to Day 2, to Week 3, and to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in Mean 24-Hour Systolic Blood Pressure (SBP) to Day 2
NCT01939496 (15) [back to overview]	Change From Baseline in Body Weight to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in Mean Daytime Diastolic Blood Pressure (DBP) to Day 2 and to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in Mean Daytime Systolic Blood Pressure (SBP) to Day 2 and to Week 6
NCT01939496 (15) [back to overview]	Change From Baseline in Mean Nighttime Diastolic Blood Pressure (DBP) to Day 2 and to Week 6
NCT01989754 (3) [back to overview]	Progression of Albuminuria
NCT01989754 (3) [back to overview]	Composite of Cardiovascular (CV) Death Events or Hospitalization for Heart Failure
NCT01989754 (3) [back to overview]	Cardiovascular (CV) Death
NCT02025907 (5) [back to overview]	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26
NCT02025907 (5) [back to overview]	Percentage of Participants With HbA1c Less Than (<) 7.0 Percent at Week 26
NCT02025907 (5) [back to overview]	Percent Change From Baseline in Body Weight at Week 26
NCT02025907 (5) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) at Week 26
NCT02025907 (5) [back to overview]	Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
NCT02065791 (8) [back to overview]	Cardiovascular (CV) Death
NCT02065791 (8) [back to overview]	Composite Endpoint of CV Death and Hospitalized Heart Failure (HHF)
NCT02065791 (8) [back to overview]	CV Composite Endpoint
NCT02065791 (8) [back to overview]	Hospitalized Heart Failure (HHF)
NCT02065791 (8) [back to overview]	Major Adverse Cardiac Event (MACE)
NCT02065791 (8) [back to overview]	Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death
NCT02065791 (8) [back to overview]	All-cause Mortality
NCT02065791 (8) [back to overview]	Renal Composite Endpoint
NCT02139943 (2) [back to overview]	Percentage of Participants With Hemoglobin A1c (HbA1c) Reduction Greater Than or Equal to (>=) 0.4 Percent (%) and no Increase in Body Weight
NCT02139943 (2) [back to overview]	Percentage of Participants With Adverse Events
NCT02220907 (4) [back to overview]	Change From Baseline in Fasting Plasma Glucose Level
NCT02220907 (4) [back to overview]	Percentage Change in Body Weight From Baseline
NCT02220907 (4) [back to overview]	Number of Participants With Adverse Events
NCT02220907 (4) [back to overview]	Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c)
NCT02220920 (5) [back to overview]	"Percentage of Participants With Adverse Events and Hypoglycemia and Blood Glucose Decreased"
NCT02220920 (5) [back to overview]	Change in Blood Pressure
NCT02220920 (5) [back to overview]	Change in Fasting Plasma Glucose
NCT02220920 (5) [back to overview]	Change in HbA1c From Baseline
NCT02220920 (5) [back to overview]	Percent Change in Body Weight
NCT02227849 (5) [back to overview]	Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events)
NCT02227849 (5) [back to overview]	Change in Blood Pressure
NCT02227849 (5) [back to overview]	Percentage Change in Body Weight
NCT02227849 (5) [back to overview]	Change in Percentage of HbA1c
NCT02227849 (5) [back to overview]	Change in Fasting Plasma Glucose
NCT02243202 (7) [back to overview]	Change From Baseline in Systolic Blood Pressure at Week 26
NCT02243202 (7) [back to overview]	Change From Baseline in Diastolic Blood Pressure (DBP) at Week 26
NCT02243202 (7) [back to overview]	Absolute Change From Baseline in Body Weight at Week 26
NCT02243202 (7) [back to overview]	Percentage of Participants With Weight Loss More Than Equal to (>=) 5 Percent at Week 26
NCT02243202 (7) [back to overview]	Percentage of Participants With Weight Loss More Than Equal to (>=) 10 Percent at Week 26
NCT02243202 (7) [back to overview]	Change From Baseline in Pulse Rate at Week 26
NCT02243202 (7) [back to overview]	Percent Change From Baseline in Body Weight at Week 26
NCT02324842 (8) [back to overview]	Change in 24-hour Blood Pressure at Study End Compared to Baseline.
NCT02324842 (8) [back to overview]	HbA1c at 4 Months
NCT02324842 (8) [back to overview]	Fasting Plasma Glucose (FPG) at 4 Months
NCT02324842 (8) [back to overview]	Change in Total Body Weight at Study End Compared to Baseline
NCT02324842 (8) [back to overview]	Change in Plasma Glucagon Concentration at the End of the Study Compared to Baseline
NCT02324842 (8) [back to overview]	Change in Matsuda Index of Insulin Sensitivity, Insulin Secretion, and Beta Cell Function During Oral Glucose Tolerance Test (OGTT)
NCT02324842 (8) [back to overview]	Change in Free Plasma Insulin at the End of the Study From Baseline Value
NCT02324842 (8) [back to overview]	Body Mass Index (BMI) at 4 Months
NCT02354222 (5) [back to overview]	Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c)
NCT02354222 (5) [back to overview]	Percentage Change in Body Weight From Baseline
NCT02354222 (5) [back to overview]	Change From Baseline in the AUC(0-2h) for Postprandial Plasma Glucose (PPG)
NCT02354222 (5) [back to overview]	Change From Baseline in Fasting Plasma Glucose Level
NCT02354222 (5) [back to overview]	Change From Baseline in 2-hour Postprandial Plasma Glucose Level
NCT02354235 (5) [back to overview]	Percentage Change in Body Weight From Baseline
NCT02354235 (5) [back to overview]	Change From Baseline in 2-hour Postprandial Plasma Glucose Level
NCT02354235 (5) [back to overview]	Change From Baseline in the AUC(0-2h) for Postprandial Plasma Glucose (PPG)
NCT02354235 (5) [back to overview]	Change From Baseline in Percentage of Glycated Hemoglobin (HbA1c)
NCT02354235 (5) [back to overview]	Change From Baseline in Fasting Plasma Glucose Level
NCT02360774 (4) [back to overview]	Change in Body Composition, Measured Using DXA Scanning.
NCT02360774 (4) [back to overview]	Change in Body Weight
NCT02360774 (4) [back to overview]	Change in Glycemic Control
NCT02360774 (4) [back to overview]	Change in Resting Energy Expenditure, Measured Using Indirect Calorimetery
NCT02462421 (6) [back to overview]	Canagliflozin-induced Change in Urinary Excretion of Sodium
NCT02462421 (6) [back to overview]	Change in Fractional Excretion of Uric Acid (the Difference Between Data After Administration of Canagliflozin Minus Data Before Administration of Canagliflozin)
NCT02462421 (6) [back to overview]	Urinary Excretion of Glucose (Measured During the 24 Hours Following Administration of Canagliflozin)
NCT02462421 (6) [back to overview]	Canagliflozin-induced Change in Serum Creatinine
NCT02462421 (6) [back to overview]	Canagliflozin-induced Change in Fasting Plasma Glucose
NCT02462421 (6) [back to overview]	Canagliflozin-induced Change in Serum Uric Acid
NCT02597049 (11) [back to overview]	Change From Baseline in 6-Point Self-Monitored Plasma Glucose (SMPG) Profile at 24 Weeks
NCT02597049 (11) [back to overview]	Change From Baseline in Body Weight at 24 Weeks
NCT02597049 (11) [back to overview]	Change From Baseline in Fasting Serum Glucose (Central Laboratory) at 24 Weeks
NCT02597049 (11) [back to overview]	Number of Participants With Adjudicated Cardiovascular (CV) Events
NCT02597049 (11) [back to overview]	Percentage of Participants With HbA1c <7%
NCT02597049 (11) [back to overview]	Rate of Hypoglycemic Events Adjusted Per 30 Days
NCT02597049 (11) [back to overview]	Change From Baseline in the HbA1c at 24 Weeks (Efficacy Estimand)
NCT02597049 (11) [back to overview]	Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand)
NCT02597049 (11) [back to overview]	Change From Baseline in Fasting Glucagon at 24 Weeks
NCT02597049 (11) [back to overview]	Number of Participants Requiring Rescue Therapy Due to Severe Persistent Hyperglycemia
NCT02597049 (11) [back to overview]	Number of Participants With Adjudicated Acute Pancreatitis Events
NCT02622113 (4) [back to overview]	Percentage Change in Body Weight
NCT02622113 (4) [back to overview]	Change in Percentage of HbA1c
NCT02622113 (4) [back to overview]	Change in Fasting Plasma Glucose
NCT02622113 (4) [back to overview]	Safety and Tolerability Assessed by Adverse Events (Number of Participants Experiencing With Adverse Events)
NCT02673138 (4) [back to overview]	Differences in Free Fatty Acid Levels Following Interruption of Basal Subcutaneous Insulin Infusion
NCT02673138 (4) [back to overview]	Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin
NCT02673138 (4) [back to overview]	Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal
NCT02673138 (4) [back to overview]	Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion
NCT02912455 (17) [back to overview]	Change at Six Months Versus Baseline in Hemoglobin A1c Value (%)
NCT02912455 (17) [back to overview]	Change in Adiponectin Levels at 6 Months Compared to Randomization
NCT02912455 (17) [back to overview]	Change in Body Weight at Six Months Compared to Baseline
NCT02912455 (17) [back to overview]	Change in CRP Levels at 6 Months Compared to Baseline
NCT02912455 (17) [back to overview]	Change in Diastolic Blood Pressure at Six Months Compared to Baseline
NCT02912455 (17) [back to overview]	Change in Fasting Glucose From Randomization
NCT02912455 (17) [back to overview]	Change in Percentage of Truncal Fat
NCT02912455 (17) [back to overview]	Change in Spine Bone Mineral Density
NCT02912455 (17) [back to overview]	Change in Percentage of Lean Mass
NCT02912455 (17) [back to overview]	Change in Percentage of Gynoid Fat
NCT02912455 (17) [back to overview]	Change in Percentage of Android Fat
NCT02912455 (17) [back to overview]	Change in Percent Body Fat as Measured by DEXA Scan at 6 Months Compared to Randomization
NCT02912455 (17) [back to overview]	Change in Leptin Levels at 6 Months Compared to Baseline
NCT02912455 (17) [back to overview]	Number of Participants Who Reported Hypoglycemia From Each Group (at a Frequency of 1 Episode)
NCT02912455 (17) [back to overview]	Change in Leg Bone Mineral Density
NCT02912455 (17) [back to overview]	Change in Total Cholesterol
NCT02912455 (17) [back to overview]	Change in Systolic Blood Pressure at 6 Months Compared to Baseline
NCT02920918 (2) [back to overview]	Change From Baseline Ventilatory Efficiency at 12 Weeks
NCT02920918 (2) [back to overview]	Change From Baseline Aerobic Exercise Capacity at 12 Weeks
NCT02964585 (18) [back to overview]	Glycemic Control
NCT02964585 (18) [back to overview]	Glycemic Control (HbA1C)
NCT02964585 (18) [back to overview]	Microalbumin
NCT02964585 (18) [back to overview]	Pulse Wave Velocity
NCT02964585 (18) [back to overview]	Resting Metabolic Rate (RMR)
NCT02964585 (18) [back to overview]	Serum Endothelial Inflammatory Markers (2)
NCT02964585 (18) [back to overview]	Augmentation Index (Pulse Wave Analysis)
NCT02964585 (18) [back to overview]	Body Fat Percentage
NCT02964585 (18) [back to overview]	eGFR
NCT02964585 (18) [back to overview]	Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Proliferation)
NCT02964585 (18) [back to overview]	Fasting Lipid Profile
NCT02964585 (18) [back to overview]	Creatinine (Urine)
NCT02964585 (18) [back to overview]	BMI
NCT02964585 (18) [back to overview]	Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Counts)
NCT02964585 (18) [back to overview]	Serum Endothelial Inflammatory Markers (1)
NCT02964585 (18) [back to overview]	Kidney Function Markers
NCT02964585 (18) [back to overview]	Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Protein Expression)
NCT02964585 (18) [back to overview]	Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Cell Percentages)
NCT03136484 (61) [back to overview]	Change in Total Fat Mass (kg)
NCT03136484 (61) [back to overview]	Change in SMPG- Mean Postprandial Increment Over All Meals
NCT03136484 (61) [back to overview]	Change in SMPG (Self-measured Plasma Glucose)- Mean 7-point Profile
NCT03136484 (61) [back to overview]	Change in SF-36: Physical Component Summary (PCS)
NCT03136484 (61) [back to overview]	Change in SF-36: Mental Component Summary (MCS)
NCT03136484 (61) [back to overview]	Change in Ratio Between Total Fat Mass and Total Lean Mass
NCT03136484 (61) [back to overview]	Change in Pulse
NCT03136484 (61) [back to overview]	Participants Who Achieved Weight Loss ≥5% (Yes/no)
NCT03136484 (61) [back to overview]	Participants Who Achieved Weight Loss ≥3% (Yes/no)
NCT03136484 (61) [back to overview]	Participants Who Achieved Weight Loss ≥10% (Yes/no)
NCT03136484 (61) [back to overview]	Participants Who Achieved HbA1c Reduction ≥1% and Weight Loss ≥5% (Yes/no)
NCT03136484 (61) [back to overview]	Participants Who Achieved HbA1c Reduction ≥1% and Weight Loss ≥3% (Yes/no)
NCT03136484 (61) [back to overview]	Participants Who Achieved HbA1c Reduction ≥1% and Weight Loss ≥10% (Yes/no)
NCT03136484 (61) [back to overview]	Participants Who Achieved HbA1c Reduction ≥1% (Yes/no)
NCT03136484 (61) [back to overview]	Participants Who Achieved HbA1c Below 7.0% (53 mmol/Mol) Without Severe or Blood Glucose (BG)-Confirmed Symptomatic Hypoglycaemia Episodes and no Weight Gain (Yes/no)
NCT03136484 (61) [back to overview]	Participants Who Achieved HbA1c ≤ 6.5% (48 mmol/Mol), American Association of Clinical Endocrinologists (AACE) Target (Yes/no)
NCT03136484 (61) [back to overview]	Participants Who Achieved HbA1c < 7.0% (53 mmol/Mol), American Diabetes Association (ADA) Target (Yes/no)
NCT03136484 (61) [back to overview]	Change in Haematological Parameter- Leukocytes
NCT03136484 (61) [back to overview]	Change in Haematological Parameter- Haemoglobin
NCT03136484 (61) [back to overview]	Change in Haematological Parameter- Haematocrit
NCT03136484 (61) [back to overview]	Change in Haematological Parameter- Erythrocytes
NCT03136484 (61) [back to overview]	Change in FPG (Fasting Plasma Glucose)
NCT03136484 (61) [back to overview]	Change in Fasting Triglycerides
NCT03136484 (61) [back to overview]	Change in Fasting Total Cholesterol
NCT03136484 (61) [back to overview]	Change in Fasting LDL-cholesterol
NCT03136484 (61) [back to overview]	Change in Fasting HDL-cholesterol
NCT03136484 (61) [back to overview]	Change in Calcitonin
NCT03136484 (61) [back to overview]	Change in Body Weight (kg)
NCT03136484 (61) [back to overview]	Change in Body Mass Index (BMI)
NCT03136484 (61) [back to overview]	Change in Vital Signs (Systolic Blood Pressure and Diastolic Blood Pressure)
NCT03136484 (61) [back to overview]	Change in Short Form 36 Health Survey (SF-36): Sub-domains
NCT03136484 (61) [back to overview]	Change in Physical Examination
NCT03136484 (61) [back to overview]	Change in HbA1c
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- Total Bilirubin
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- Sodium
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- Potassium
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- Lipase
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- eGFR
NCT03136484 (61) [back to overview]	Change in Haematological Parameter- Thrombocytes
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- Calcium
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- AST
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- Amylase
NCT03136484 (61) [back to overview]	Change in ECG
NCT03136484 (61) [back to overview]	Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ): Treatment Satisfaction Summary Score (Sum of 6 of 8 Items) and the 8 Items Separately
NCT03136484 (61) [back to overview]	Change in Control of Eating Questionnaire (CoEQ): Domains
NCT03136484 (61) [back to overview]	Change in CoEQ: Individual Items
NCT03136484 (61) [back to overview]	Total Number of Treatment-emergent Severe or Blood Glucose-confirmed Symptomatic Hypoglycaemic Episodes
NCT03136484 (61) [back to overview]	Total Number of Treatment Emergent Adverse Events (TEAEs)
NCT03136484 (61) [back to overview]	Percentage Change in Visceral Fat Mass (%)
NCT03136484 (61) [back to overview]	Percentage Change in Total Lean Mass (%)
NCT03136484 (61) [back to overview]	Percentage Change in Total Fat Mass (%)
NCT03136484 (61) [back to overview]	Eye Examination
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- ALT
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- ALP
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- Albumin
NCT03136484 (61) [back to overview]	Participants With Treatment-emergent Severe or Blood Glucose-confirmed Symptomatic Hypoglycaemic Episodes
NCT03136484 (61) [back to overview]	Change in Waist Circumference
NCT03136484 (61) [back to overview]	Change in Visceral Fat Mass (kg)
NCT03136484 (61) [back to overview]	Percentage Change in Body Weight (%)
NCT03136484 (61) [back to overview]	Change in Total Lean Mass (kg)
NCT03136484 (61) [back to overview]	Change in Biochemistry Parameter- Creatinine
NCT03267576 (15) [back to overview]	Change From Baseline in Percentage of 2 Consecutive Glucose Readings With < 70 mg/dL
NCT03267576 (15) [back to overview]	Change From Baseline in Time Spent With Glucose Level < 70 mg/dL
NCT03267576 (15) [back to overview]	Change From Baseline in Time Spent With Glucose Level > 140 mg/dL
NCT03267576 (15) [back to overview]	Change From Baseline in Time Spent With Glucose Level > 180 mg/dL
NCT03267576 (15) [back to overview]	Change From Baseline in Time Spent With Glucose Level 70 to 139 mg/dL
NCT03267576 (15) [back to overview]	Percent Change From Baseline in Time During 24 Hours With Glucose 70 to 139 mg/dL
NCT03267576 (15) [back to overview]	Percent Change From Baseline in Time During 24 Hours With Glucose Greater Than (>) 140 mg/dL
NCT03267576 (15) [back to overview]	Percent Change From Baseline in Time During 24 Hours With Glucose Level > 180 mg/dL
NCT03267576 (15) [back to overview]	Percent Change From Baseline in Time During 24 Hours With Glucose Level Less Than (<) 70 mg/dL
NCT03267576 (15) [back to overview]	Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 1
NCT03267576 (15) [back to overview]	Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 2
NCT03267576 (15) [back to overview]	Change From Baseline in 2-hour Post-prandial Glucose (PPG) Levels
NCT03267576 (15) [back to overview]	Change From Baseline in Fasting Plasma Glucose Levels
NCT03267576 (15) [back to overview]	Change From Baseline in Glycemic Standard Deviation (SD) for 24-hour Glucose Profile
NCT03267576 (15) [back to overview]	Change From Baseline in Mean 24-hour Glucose Profile
NCT04252287 (5) [back to overview]	Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 12
NCT04252287 (5) [back to overview]	Change From Baseline in KCCQ Clinical Summary Score at Week 12
NCT04252287 (5) [back to overview]	Change From Baseline in KCCQ Overall Summary Score at Week 12
NCT04252287 (5) [back to overview]	Change From Baseline in Total Daily Step Count at Week 12
NCT04252287 (5) [back to overview]	Change From Baseline in KCCQ Individual Domain Scores (Physical Limitation and Quality of Life) at Week 12
NCT04288778 (4) [back to overview]	Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24
NCT04288778 (4) [back to overview]	Percentage of Participants With Unexpected Adverse Events (AEs)
NCT04288778 (4) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
NCT04288778 (4) [back to overview]	Percentage of Participants With Adverse Drug Reactions (ADRs)

Percent Change in Body Weight From Baseline to Week 12

The table below shows the mean percent change in body weight from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

Intervention	Percent change (Mean)
Placebo	-1.1
Canagliflozin 50 mg Daily	-2.3
Canagliflozin 100 mg Daily	-2.6
Canagliflozin 200 mg Daily	-2.7
Canagliflozin 300 mg Daily	-3.4
Canagliflozin 300 mg Twice Daily	-3.4
Sitagliptin 100 mg Daily	-0.6

Intervention	kg (Mean)
Placebo	-0.78
Canagliflozin 50 mg Daily	-1.96
Canagliflozin 100 mg Daily	-2.25
Canagliflozin 200 mg Daily	-2.32
Canagliflozin 300 mg Daily	-2.88
Canagliflozin 300 mg Twice Daily	-2.87
Sitagliptin 100 mg Daily	-0.43

Intervention	mg/mg (Mean)
Placebo	1.9
Canagliflozin 50 mg Daily	35.4
Canagliflozin 100 mg Daily	51.5
Canagliflozin 200 mg Daily	50.5
Canagliflozin 300 mg Daily	49.4
Canagliflozin 300 mg Twice Daily	61.6
Sitagliptin 100 mg Daily	-1.9

Intervention	Percent (Mean)
Placebo	-0.22
Canagliflozin 50 mg Daily	-0.79
Canagliflozin 100 mg Daily	-0.76
Canagliflozin 200 mg Daily	-0.70
Canagliflozin 300 mg Daily	-0.92
Canagliflozin 300 mg Twice Daily	-0.95
Sitagliptin 100 mg Daily	-0.74

Intervention	mmol/L (Mean)
Placebo	0.2
Canagliflozin 50 mg Daily	-0.9
Canagliflozin 100 mg Daily	-1.4
Canagliflozin 200 mg Daily	-1.5
Canagliflozin 300 mg Daily	-1.4
Canagliflozin 300 mg Twice Daily	-1.3
Sitagliptin 100 mg Daily	-0.7

Intervention	cm (Mean)
Placebo	-1.2
Canagliflozin 50 mg	-1.4
Canagliflozin 100 mg	-2.9
Canagliflozin 300 mg	-2.6

Intervention	cm (Mean)
Placebo	0.1
Canaglifozin 50 mg	-2.0
Canagliflozin 100 mg	-2.1
Canagliflozin 300 mg	-3.0

Intervention	kg/m2 (Mean)
Placebo	-0.4
Canagliflozin 50 mg	-0.7
Canagliflozin 100 mg	-1.0
Canagliflozin 300 mg	-0.9

Intervention	Percentage of patients (Number)
Placebo	8.1
Canagliflozin 50 mg	12.6
Canagliflozin 100 mg	18.8
Canagliflozin 300 mg	17.2

Intervention	ratio (Mean)
Placebo	-0.011
Canaglifozin 50 mg	0.003
Canagliflozin 100 mg	-0.008
Canagliflozin 300 mg	-0.004

Intervention	Percent (Least Squares Mean)
Canagliflozin 100 mg	-0.65
Canagliflozin 300 mg	-0.74
Glimepiride	-0.55

Intervention	Percent (Least Squares Mean)
Canagliflozin 100 mg	-0.82
Canagliflozin 300 mg	-0.93
Glimepiride	-0.81

Intervention	Percent change (Least Squares Mean)
Canagliflozin 100 mg	-4.2
Canagliflozin 300 mg	-4.7
Glimepiride	1.0

Intervention	HbA1c (%) (Least Squares Mean)
Placebo	0.01
Canagliflozin 100 mg	-0.26
Canagliflozin 300 mg	-0.31

Intervention	Millimoles per liter (mmol/L) (Least Squares Mean)
Placebo	0.16
Canagliflozin 100 mg	-0.42
Canagliflozin 300 mg	-0.57

Intervention	mL/min/1.73 m^2 (Least Squares Mean)
Placebo	-5.23
Canagliflozin 100 mg	-3.55
Canagliflozin 300 mg	-3.98

Intervention	Millimeter of mercury (mmHg) (Least Squares Mean)
	SBP(Change at end of treatment)	DBP (Change at end of treatment)
Canagliflozin 100 mg	-4.91	-3.70
Canagliflozin 300 mg	-6.49	-4.51
Placebo	-1.96	-2.88

Intervention	mmol/L (Least Squares Mean)
	Cholesterol (change at EOT)	HDL-C (change at EOT)	LDL-C (change at EOT)
Canagliflozin 100 mg	0.11	0.04	0.04
Canagliflozin 300 mg	0.16	0.05	0.10
Placebo	-0.07	-0.01	-0.07

Intervention	Percent change (Least Squares Mean)
Placebo	-0.50
Canagliflozin 100 mg	-3.47
Canagliflozin 300 mg	-4.12

Intervention	Events per 1000 patient-year (Number)
Placebo	30.36
Canagliflozin 100 mg	28.41
Canagliflozin 300 mg	25.37
Canagliflozin (Total)	26.89

Intervention	Milligram per gram (mg/g) (Geometric Mean)
Placebo	29.30
Canagliflozin 100 mg	25.50
Canagliflozin 300 mg	24.47

canagliflozin

Description

Cross-References

Synonyms (63)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (3)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (18)

Molecular Functions (12)

Ceullar Components (10)

Bioassays (20)

Research

Studies (976)

Market Indicators

Research Demand Index: 84.39

Study Types

Clinical Trials (133)

Trial Overview

Trial Outcomes

Percent Change in Body Weight From Baseline to Week 12

Absolute Change in Body Weight From Baseline to Week 12

Change in Overnight Urine Glucose/Creatinine Ratio From Baseline to Week 12

Change in HbA1c From Baseline to Week 12

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 12

Percentage of Patients With Symptoms of Hypoglycemia

Change in Waist Circumference From Baseline to Week 12

Change in Hip Circumference From Baseline to Week 12

Change in Body Mass Index (BMI) From Baseline to Week 12

Absolute Change in Body Weight From Baseline to Week 12

Percentage of Patients Who Lost at Least 5% of Their Initial Body Weight by Week 12

Percentage of Patients Who Lost at Least 10% of Their Initial Body Weight by Week 12

Percent Change in Body Weight From Baseline to Week 12

Change in Waist/Hip Ratio From Baseline to Week 12

Change in HbA1c From Baseline to Week 104

Change in HbA1c From Baseline to Week 52

Percent Change in Body Weight From Baseline to Week 52

Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52

Change From Baseline in Homeostasis Model Assessment 2 Steady-State Beta-Cell Function (HOMA2-%B) at the End-of-Treatment (EOT)

Change From Baseline in Glycated Hemoglobin (HbA1c) at End-of-Treatment

Change From Baseline in Fasting Plasma Glucose (FPG) Levels at End-of-Treatment

Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at End-of-Treatment

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End-of-Treatment

Change From Baseline in Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) Levels at End-of-Treatment

Percentage of Participants With Progression of Albuminuria at the End-of-Treatment

Percent Change From Baseline in Body Weight at End-of-Treatment

Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke

Change From Baseline in Urinary Albumin/Creatinine Ratio at End-of-Treatment

Change From Baseline in Triglycerides Levels at End-of-Treatment

Change From Baseline in Proinsulin/Insulin (PI/I) Ratio at the End-of-Treatment

Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment

Change in HbA1c From Baseline to Week 26

Percentage of Patients With HbA1c <7% at Week 26

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26

Change in HbA1c From Baseline to Week 26 (Main Study)

Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (High Glycemic Substudy)

Percent Change in Body Weight From Baseline to Week 26 (Main Study)

Percent Change in Body Weight From Baseline to Week 26 (High Glycemic Substudy)

Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (Main Study)

Change in Systolic Blood Pressure (SBP) From Baseline to Week 26 (High Glycemic Substudy)

Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (High Glycemic Substudy)

Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy)

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (Main Study)

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26 (High Glycemic Substudy)

Change in 2-hour Post-prandial Glucose From Baseline to Week 26 (Main Study)

Percentage of Patients With HbA1c <7% at Week 26 (Main Study)

Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26 (Main Study)

Percent Change in Triglycerides From Baseline to Week 26 (High Glycemic Substudy)

Intervention	Ratio (Least Squares Mean)
Placebo	-0.04
Canagliflozin 100 mg	-0.02
Canagliflozin 300 mg	0.00

Intervention	Percent (Least Squares Mean)
Placebo	-0.03
Canagliflozin 100 mg	-0.33
Canagliflozin 300 mg	-0.44

Intervention	mg/dL (Least Squares Mean)
Placebo	0.49
Canagliflozin 100 mg	-14.9
Canagliflozin 300 mg	-11.7

Intervention	Percent (Least Squares Mean)
Placebo	0.14
Canagliflozin 100 mg	-0.77
Canagliflozin 300 mg	-1.03

Intervention	mmHg (Least Squares Mean)
Placebo	0.38
Canagliflozin 100 mg	-3.34
Canagliflozin 300 mg	-5.04

Intervention	mg/dL (Least Squares Mean)
Placebo	8.33
Canagliflozin 100 mg	-27.2
Canagliflozin 300 mg	-35.0

Intervention	mg/dL (Least Squares Mean)
Placebo	5.19
Canagliflozin 100 mg	-42.9
Canagliflozin 300 mg	-58.8

Intervention	mmHg (Least Squares Mean)
Placebo	-2.65
Canagliflozin 100 mg	-4.89
Canagliflozin 300 mg	-4.27

Intervention	mg/dL (Least Squares Mean)
Placebo	4.11
Canagliflozin 100 mg	-18.2
Canagliflozin 300 mg	-30.5

Intervention	Percent (Least Squares Mean)
Placebo	-0.13
Canagliflozin 100 mg	-0.85
Canagliflozin 300 mg	-1.06